Infusion of CCR5 Gene-Edited T Cells Allows Immune Reconstitution, HIV Reservoir Decay, and Long-Term Virological Control

Joumana Zeidan^{1*φ}, Ashish A. Sharma^{1,2*}, Gary Lee³, Angie Raad⁴, Remi Fromentin^{5,6}, Slim Fourati^{1,2}, Khader Ghneim^{1,2}, Gabriela P. Sanchez^{1,2}, Clarisse Benne¹, Glenda Canderan¹, Francesco A. Procopio⁷, Robert Balderas⁸, Georges Monette⁴, Jacob P. Lalezari⁹, Jane M. Heffernan⁴, Laurent Sabbagh⁵, Nicolas Chomont^{5,6}, Dale Ando^{3¶}, Steven G. Deeks¹⁰, and Rafick-Pierre Sekaly^{1,2φ}

¹Case Western Reserve University, Cleveland, Ohio, USA

²Emory University, Atlanta, Georgia, USA

³Sangamo Therapeutics, Richmond, California, USA

⁴Centre for Disease Modelling, Mathematics & Statistics, York University, Toronto, Ontario, Canada

⁵Université de Montréal, Faculty of Medicine, Department of Microbiology, Infectiology, and Immunology, Montreal, Quebec, Canada

⁶Université de Montréal, Centre de Recherche du CHUM, Montreal, Quebec, Canada

⁷Lausanne University Hospital (CHUV), Lausanne, Switzerland

⁸BD Biosciences, San Jose, California, USA

⁹Quest Clinical Research, San Francisco, California, USA

¹⁰University of California, San Francisco and San Francisco General Hospital, San Francisco, California, USA

**Both authors contributed equally to this work.*

φRafick-Pierre Sekaly and Joumana Zeidan are the corresponding authors for this manuscript. Please direct all inquiries to: rafick.sekaly@emory.edu

¶Deceased.

Abstract

Antiretroviral therapy (ART) fails to fully restore immune function and is not curative. A single infusion of CCR5 gene-edited autologous CD4⁺ T cells (SB-728-T) led to sustained increases in CD4⁺ T cell counts, improved T cell homeostasis, and reduced the estimated size of the HIV reservoir. These outcomes were associated with the expansion and long-term persistence of a novel CCR5 gene-edited CD4⁺ T memory stem cell (CD45RA^{int}RO^{int} T_{SCM}) subset that can replenish the pool of more differentiated memory cells. We showed that novel CD45RA^{int}RO^{int} T_{SCM} cells are transcriptionally distinct from the previously described CD45RA⁺ T_{SCM} and are minimally differentiated cells uncommitted to a specific Th-lineage. Subsequently, we showed in an independent trial that infusion of the SB-728-T cell product resulted in partial control of viral replication upon cessation of ART which was correlated with the frequencies of CCR5 gene-edited T_{SCM} and their T_{EM} progeny. Interestingly, one participant that remained off ART to this date demonstrated long-term maintenance of CCR5 gene-edited cells and increased frequency of polyfunctional HIV-specific CD4⁺ and CD8⁺ T cells, contributing to low levels of viral load 5 years post-infusion. Consequently, the generation of HIV protected memory CD4⁺ T cells by CCR5 disruption can contribute toward novel interventions aimed at achieving a sustained ART-free viral remission of HIV disease.

54 Introduction

55 Although ART can durably suppress viral replication, HIV persists indefinitely, requiring
 56 infected individuals to remain on complex antiretroviral drug regimens for life. The
 57 ability of ART to reconstitute immune function is highly variable. A subset of individuals
 58 who initiate ART later in the disease course (10% to 45%, i.e., “immune non-
 59 responders”) fail to exhibit complete restoration of CD4⁺ T cell counts even after years of
 60 effective ART¹. Diminished CD4⁺ T cell recovery has been associated with several host-
 61 related and HIV-related factors such as impaired thymopoiesis and homeostasis²⁻⁴. As
 62 low CD4⁺ T cell counts in individuals on ART have been associated with increased risk
 63 of cardiovascular complications, cancer and other comorbidities⁵⁻⁸, novel therapeutic
 64 approaches to restore immune homeostasis are needed.

65 Studies quantifying the latent HIV reservoir have shown minimal decay of total and
 66 integrated HIV DNA four years post ART initiation, particularly in participants who
 67 received ART only during the chronic phase of infection^{9,10}. Several mechanisms
 68 contribute to HIV persistence including “latent” infection of long-lived memory CD4⁺ T
 69 cells¹¹⁻¹³ that are maintained by homeostatic proliferation¹⁴⁻¹⁶ and dysfunctional host
 70 clearance mechanisms^{2,17}. Intriguingly, these mechanisms are exacerbated in immune
 71 non-responders^{3,18,19} and have been associated with higher frequencies of HIV-infected
 72 cells²⁰. Therefore, enhancing the recovery of CD4⁺ T cells may contribute to the
 73 reduction of the HIV reservoir during ART.

74 CCR5 is one of the major co-receptors for HIV entry. The therapeutic advantage of
 75 providing HIV-infected individuals with a CCR5-deficient immune compartment was

demonstrated with the “Berlin Patient”^{21,22}, who was HIV-free since receiving allogeneic bone marrow transplants of CD34⁺ stem cells from a homozygous CCR5Δ32 matched donor. While these results are encouraging, a less invasive and a more broadly applicable curative strategy would be desirable. One approach is to reconstitute immune function through adoptive transfer of autologous T cells which has shown promising results in other viral infections, including cytomegalovirus and Epstein-Barr virus^{23,24}, but largely failed in HIV infection²⁵⁻²⁸, partly because CD4⁺ T cells remain susceptible to HIV infection. Perez *et al.*, demonstrated that HIV-infected NOD/SCID/IL-2Rγ^{null} mice transplanted with CCR5 gene-edited cells had higher CD4⁺ T cells and lower plasma viremia compared to mice that received mock CD4⁺ T cells²⁹. In addition, a clinical trial with adoptively transferred zinc finger nuclease (ZFN)-mediated CCR5 gene-edited CD4⁺ T cells (SB-728-T products) in HIV-infected adults demonstrated that infusion was safe, well tolerated and led to increased CD4⁺ T cell counts³⁰. Herein, we show in two independent clinical trials that expansion of CD45RA^{int}RO^{int} T_{SCM} and resetting of T cell homeostasis is a mechanism that underlies the long-term benefits of this intervention.

Results

A novel memory stem cell-like CD4⁺ T cell subset contributes to restoration of T cell homeostasis and correlates with reservoir decay.

The clinical study SB-728-0902 evaluated nine HIV-infected immune non-responders on long-term ART (7-22 years) who had at baseline a mean CD4⁺ T cell count of 363 cells/μL (Supplementary Table 1).

All participants received a single infusion of 1×10^{10} to 3×10^{10} SB-728-T product containing between 14% to 36% ZFN-mediated CCR5 gene-edited alleles (3 cohorts, $n = 9$; see online Methods and **Supplementary Table 2**). The infused product was devoid of naïve cells and included mostly ($34\% \pm 16$) effector memory cells (T_{EM}) and a population that expressed intermediate levels of both CD45RA and CD45RO ($CD45RA^{int}RO^{int}$; mean of $31\% \pm 17$). A subset of $CD45RA^{int}RO^{int}$ cells ($14.5\% \pm 7.05$) also expressed CD27 and CCR7 (**Supplementary Fig. 1a, b**). $CD45RA^{int}RO^{int}CD27^{+}CCR7^{+}$ cells had the highest levels of gene edited alleles in SB-728-T (45.9% vs. 37.9% in T_{EM} , $P = 0.002$; **Supplementary Fig. 1c**), as determined by deep sequencing of the CCR5 allele. The frequency of cells harboring integrated HIV DNA in the product was significantly lower than that of pre-manufacture cells ($P = 0.0039$; **Supplementary Fig. 1d**). The frequency of integrated HIV DNA was significantly lower in $CD45RA^{int}RO^{int}CD27^{+}CCR7^{+}$ cells from SB-728-T products than in other memory subsets (mean of 58.11 copy/ 10^6 cells vs. 679.4 copy/ 10^6 cells in T_{EM} , $P = 0.0078$; **Supplementary Fig. 1e**).

CCR5 gene-edited cells expanded post infusion and peaked at 7-21 days (median 2.4-fold expansion at 21 days; **Supplementary Fig. 2a**). CCR5 gene-edited $CD4^{+}$ T cells, assessed by the Pentamer Duplication assay (a measure of a specific five-nucleotide insertion at the site of ZFN-mediated editing that represents ~25% of all modified sequences^{29,30}) and DNA-Seq of the CCR5 locus, were detected up to 3-4 years in PBMCs (**Supplementary Table 2**), with frequencies of gene-edited alleles in $CD4^{+}$ T cells ranging between 5 and 15.7% ($n = 5$; **Supplementary Fig. 2b**), and up to 12 months (last sampled time point) in rectal mucosal biopsies (**Supplementary Fig. 2c**). In addition, the frequency of edited mononuclear cells in lymph node tissues ($n = 3$) was

similar to that found in the periphery (**Supplementary Fig. 2d**). Consequently, peripheral CD4⁺ T cells counts also increased post-infusion (**Supplementary Table 2 and Supplementary Fig. 2e**), similar to the findings of Tebas *et al.*³⁰, and remained significantly above baseline (BL) for 3-4 years post-infusion (+162 cells/ μ L, $P = 0.02$; **Supplementary Fig. 2e**). The infusion dose (CCR5 gene-edited cell numbers) did not correlate with peak or long-term CD4⁺ T cell counts ($P = 0.95$ and $P = 0.91$; data not shown). Increased CD4⁺ T cell counts and the restoration of the CD4:CD8 ratio (mean of 0.62 at BL vs. at 0.84 month 12, $P = 0.0078$; data not shown) were associated with the expansion of gene-edited cells post-infusion (**Supplementary Table 3**).

To identify the mechanisms leading to the reconstitution of CD4⁺ T cells, a longitudinal analysis of the distribution of CD4⁺ T cell subsets post-infusion was performed. We found a specific increase in the frequency and absolute numbers of CD4⁺ T cells expressing intermediate levels of CD45RA and CD45RO (termed “CD45RA^{int}RO^{int}”) at every time point analyzed post-infusion (from 13.8% at BL to 38.9% at day 14-28 ($P = 0.03$) and 25.4% at year 3-4 ($P = 0.008$); **Fig. 1a and Supplementary Fig. 3a and b**). CD45RA^{int}RO^{int} cells expressed markers previously shown to be up-regulated on CD45RA⁺ memory stem cells (CD45RA⁺ T_{SCM})³¹, such as CD127, CD28, CD58 and CD95³² (**Fig. 1b**), suggesting that this subset could represent a novel T_{SCM} subset. Increased CD45RA^{int}RO^{int} T_{SCM} counts (**Supplementary Fig. 3c**), but not that of any other memory subsets, were significantly correlated with long-term increases of CD4⁺ T cell counts (**Table 1**) as well as with long-term frequencies of CCR5 gene-edited CD4⁺ T cells ($P = 0.0002$, **Supplementary Fig. 3d**). Consequently, levels of the Pentamer Duplication marker were specifically enriched within CD45RA^{int}RO^{int} T_{SCM} post-infusion

with a mean of 10- and 38-fold higher levels in CD45RA^{int}RO^{int} T_{SCM} compared to central memory (T_{CM}) or effector memory (T_{EM}) cells at years 3-4, respectively (**Fig. 1c**). Sequencing of CCR5 DNA mutations confirmed the long-term enrichment of CCR5 gene-edited alleles in CD45RA^{int}RO^{int} T_{SCM} (23% ± 11 CCR5 gene-edited alleles at year 3-4 compared to 7.9% ± 5.1 in T_{CM} ($P = 0.02$) and 5.9% ± 6.6 in T_{TM} ($P = 0.02$); **Supplementary Fig. 3e**). Importantly, expansion of CD45RA^{int}RO^{int} T_{SCM} post infusion was associated with a polyclonal reconstitution of the CD4⁺ T cell compartment as no changes were observed in CCR5 insertion/deletion (indel) diversity (**Supplementary Fig. 3f**) and in TCR diversity, as measured by similar Shannon entropy indexes³³ (**Supplementary Fig. 3g**), post infusion.

The presence of CCR5 gene mutations in short-lived memory cells such as T_{EM} at years 3-4 post-infusion (0.7% to 3% CCR5 gene-edited alleles; **Supplementary Fig. 3e**) suggested that CCR5 gene-edited cells within long-lived memory cells such as T_{SCM} can differentiate and maintain a small subset of CCR5 gene-edited T_{EM} cells years after the initial infusion. We identified CCR5 ZFN-mediated indels unique to the CD45RA^{int}RO^{int} T_{SCM} subset in SB-728-T products ($n = 3,881$) that remained detected in CD45RA^{int}RO^{int} T_{SCM} at 3-4 years post infusion, demonstrating their capacity to persist long-term. Additionally, CD45RA^{int}RO^{int} T_{SCM}-unique indels were detected in other memory T cell subsets post-infusion including short-lived T_{EM} at 3-4 years post infusion (0.49% (95% CI: 0%-1.36%); **Fig. 1d**), suggesting the potential of these cells to generate more differentiated cells. The detection of CD45RA^{int}RO^{int} T_{SCM}-unique indels in the CD45RA⁺ T_{SCM} subset (**Fig. 1d**) as well as the detection of high levels of the Pentamer Duplication marker in these cells (**Fig. 1d**) suggest that the increase in CD45RA⁺ T_{SCM}

(**Supplementary Fig. 3c**) post infusion is a result of their differentiation from CD45RA^{int}RO^{int} T_{SCM} post infusion and not from homeostatic proliferation.

To investigate the potential of CD45RA^{int}RO^{int} T_{SCM} cells to undergo homeostatic expansion or self-renewal and differentiate into other memory subsets following *in vitro* stimulation, CD45RA^{int}RO^{int} T_{SCM} cells were sorted at year 3-4, labelled with CellTrace Violet (CTV), and cocultured with anti-CD3/CD28 Dynabeads and homeostatic cytokines (**Fig. 1e**). At days 4 and 6, the majority of cells had undergone proliferation (91% and 97% CTV low cells, respectively; **Supplementary Fig. 4a**). Cells of the CD45RA^{int}RO^{int} phenotype remained detected throughout culture while CD45RO⁺ memory T cells increased progressively (**Fig. 1f**). Interestingly, CD45RA⁺ T_{SCM} peaked at day 2 and were detected in cells undergoing 0-1 rounds of proliferation (**Fig. 1f and Supplementary Fig. 4b**), suggesting that this subset has limited self-renewal capacity and/or is more prone to undergo differentiation with increased cell proliferation. Uniform Manifold Approximation and Projection (UMAP), a non-linear dimensionality reduction technique³⁴, was employed to investigate the modulation of markers associated with self-renewal and Th-lineage commitment throughout cell division in culture. Two PhenoGraph clusters were identified (**Fig. 1g and Supplementary Fig. 4c**); cluster 13, which was the most abundant cluster in cells with one cycle of proliferation, decreased in frequencies during proliferation and maintained the CD45RA^{int}RO^{int} T_{SCM} phenotype and expression of CD27, CCR7, 41BB, and TCF-7, and cluster 6 which increased during proliferation, consisted of the main cluster in cells with 4+ cycles of proliferation, and up-regulated expression of CD45RO, T-bet and GATA-3 (**Fig. 1h and Supplementary Fig. 4d**). All together, these results indicate that CD45RA^{int}RO^{int} T_{SCM} cells most likely

represent a novel long-lived memory subset that contributes to the long-term polyclonal persistence of CCR5 gene-edited cells and confirm that $CD45RA^{int}RO^{int} T_{SCM}$ cells can differentiate into and replenish the pool of more differentiated memory cells.

A single SB-728-T infusion led to a continuous decrease in the frequency of HIV-infected cells that correlates with the persistence and differentiation of CCR5 gene-edited $CD45RA^{int}RO^{int} T_{SCM}$ cells.

Infusion of SB-728-T led to significantly lower frequencies of total HIV DNA in PBMCs at 2 years ($P = 0.02$; **Fig. 2a and Supplementary Table 4**) compared to baseline. Moreover, the frequencies of $CD4^{+}$ T cells with integrated HIV DNA significantly declined at 3-4 years post-infusion ($P = 0.004$; **Fig. 2b**) and correlated with the frequencies of total HIV proviruses, as measured by the intact proviral DNA assay (IPDA) ($P = 0.02$; **Fig. 2c**). These results suggest that expansion and persistence of infused CCR5 gene-edited $CD4^{+}$ T cells have an impact on the decay of the HIV reservoir size.

As $CD45RA^{int}RO^{int} T_{SCM}$ cells had significantly lower levels of integrated HIV DNA post-infusion compared to other memory subsets ($P < 0.05$; **Supplementary Fig. 5a**) and minimal contribution to the pool of HIV-infected $CD4^{+}$ T cells ($P < 0.05$; **Supplementary Fig. 5b**) in year 3-4 samples, we investigated the impact of persistence and differentiation of $CD45RA^{int}RO^{int} T_{SCM}$ post-infusion on the reservoir decay, using a sparse linear multivariate model to identify features (**Supplementary Table 5**) that could predict the change in the frequency of PBMCs harboring total HIV DNA post-infusion.

This model indicated that a greater decay in the HIV reservoir post-infusion was best predicted by higher $CD45RA^{int}RO^{int} T_{SCM}$ cell counts at years 3-4 ($P = 0.002$), higher frequencies of Pentamer Duplication in $CD45RA^{int}RO^{int} T_{SCM}$ at years 3-4 ($P = 0.005$), and a lower ratio of the frequency of Pentamer Duplication in $CD45RA^{int}RO^{int} T_{SCM}$ over the frequency of Pentamer Duplication in T_{EM} at years 3-4 ($P = 0.001$), reflecting the differentiation of CCR5 gene-edited $CD45RA^{int}RO^{int} T_{SCM}$ into the T_{EM} subset (adjusted $r^2 = 0.99$, F-test: $P = 0.0008$; **Fig. 2d**).

Linear regression analysis of genesets of sorted $CD45RA^{int}RO^{int} T_{SCM}$ cells post infusion with the decay of HIV reservoir (total HIV DNA ratio) showed that pathways associated with homeostatic proliferation (STAT-5 signaling) and stemness (Wnt signaling) were correlated with a greater decay in HIV DNA 2 years post infusion (**Fig. 2e**), demonstrating that the pathways crucial for T_{SCM} homeostasis are also involved in the observed decay of HIV-infected cells^{35,36} (**Supplementary Fig. 5c and Supplementary Table 6**). As $CD45RA^{int}RO^{int} T_{SCM}$ cells harbor significantly lower levels of HIV-infected cells than other memory subsets (**Supplementary Figs. 1e, 5a, 5b**), our results suggest that long-term persistence of CCR5 gene-edited $CD45RA^{int}RO^{int} T_{SCM}$ can lead to a reduction in the size of the HIV reservoir as a result of these cells differentiating into and replenishing the pool of more differentiated T_{EM} .

$CD45RA^{int}RO^{int} T_{SCM}$ are distinct from the previously described $CD45RA^{+} T_{SCM}$ and are minimally differentiated cells uncommitted to a specific Th-lineage.

Transcriptional analysis of sorted $CD4^{+}$ T cell subsets was performed on samples from 3-4 years post-infusion. Multi-dimensional scaling of gene expression variance and

233 differential gene expression analysis showed greater dissimilarity between
 234 $CD45RA^{int}RO^{int} T_{SCM}$ and T_{CM} and T_{EM} than with $CD45RA^{+} T_{SCM}$ (**Supplementary Fig.**
 235 **6a,b**). Our results also indicated that $CD45RA^{int}RO^{int} T_{SCM}$ were transcriptionally distinct
 236 from the $CD45RA^{+} T_{SCM}$ subset previously described^{31,32}. Figure 3a shows that
 237 $CD45RA^{+} T_{SCM}$ expressed several genes associated with T cell activation (e.g., TOX,
 238 LAG-3) and effector function (e.g., Perforin, IFN- γ , Granzyme B). $CD45RA^{int}RO^{int}$
 239 T_{SCM} showed upregulated levels of ID3, CCR7, and CD27, all markers of
 240 undifferentiated mature memory $CD4^{+}$ T cells^{37,38} (**Fig. 3a**). SLEA analysis (**Fig. 3b** and
 241 **Supplementary Table 7**) further demonstrates that $CD45RA^{int}RO^{int} T_{SCM}$ show
 242 downregulation of genes associated with activation and cell cycling pathways. Definite
 243 demonstration that these two subsets are distinct is also shown in Fig. 3b, where the
 244 pathways associated with T cell stemness³¹ were found to be enriched in $CD45RA^{int}RO^{int}$
 245 T_{SCM} compared to $CD45RA^{+} T_{SCM}$.

246 Further indication that $CD45RA^{int}RO^{int} T_{SCM}$ cells are uncommitted to a specific Th
 247 lineage is demonstrated by the lack of expression of the transcription factors associated
 248 with Th1 (T-bet and Eomes), Th2 (GATA-3), and Th17 (ROR γ t) subsets (**Fig. 3c**).
 249 Moreover, upon TCR stimulation of PBMCs at 3-4 years post-infusion, a cluster of cells
 250 comprised of $CD45RA^{int}RO^{int} T_{SCM}$ produced IL-2, MIP-1a, and TNF- α but not the
 251 effector cytokine IFN- γ (**Fig. 3d-g**). In contrast, T_{EM} produced the highest levels of the
 252 effector cytokines TNF- α and IFN- γ upon stimulus (**Fig. 3f,g**). Altogether, these results
 253 confirmed that $CD45RA^{int}RO^{int} T_{SCM}$ cells constitute a novel T_{SCM} subset with features of
 254 quiescent uncommitted and long-lived memory $CD4^{+}$ T cells; importantly, these features

are associated with the above observed decay of the HIV reservoir as well with immune reconstitution.

CCR5 gene-edited CD45RA^{int}RO^{int} T_{SCM} correlate with control of viral load in participants who underwent treatment interruption 6 weeks post-SB-728-T infusion.

We assessed the impact of infusion of CCR5 gene-edited CD4⁺ T cells, including CD45RA^{int}RO^{int} T_{SCM}, on control of viremia upon cessation of ART in an independent clinical trial (SB-728-1101 study). Participants received escalating doses of cyclophosphamide (CTX) two days prior to infusion (5 cohorts, $n = 15$; see online Methods and **Supplementary Table 8**) and underwent an analytical treatment interruption (ATI) six weeks post-infusion of SB-728-T products. Enrichment of CCR5 mutations within the CD45RA^{int}RO^{int} T_{SCM} ($27.8\% \pm 10.4$ gene-edited alleles compared to $13.3\% \pm 4.7$ in T_{CM} ($P = 0.02$) and $18.8\% \pm 6.3$ in T_{TM} ($P = 0.02$); **Supplementary Fig. 7a**) was confirmed in SB-728-T products, likely a consequence of their capacity to self-renew and persist. Analysis of viral load (VL) levels showed significantly lower VL during ATI (at week 22) than the historic pre-ART VL set-point ($P = 0.0054$; **Fig. 4a**), indicating that infusion of SB-728-T products may have led to transient but incomplete control of viremia in the majority of the participants. Six individuals who at week 22 showed VL measurements below 10,000 copies/mL and CD4⁺ T cell counts above 500 cells/ μ L opted to extend ATI beyond week 22 (and remained on ATI for 0.5 – 5 years; **Supplementary Fig. 7b and Supplementary Table 9**). Amongst them, participants who showed a reduction of week 22 VL compared to the historic pre-ART VL greater than 0.5 log were labelled as post-treatment virologic controllers (PTCs). PTCs showed significantly lower levels of infected cells after 16 weeks of ATI than non-controllers, as

measured by integrated HIV DNA, as well as total and intact proviruses quantified with the IPDA assay (**Fig. 4b**). Frequencies of CD4⁺ T cells with intact proviruses after 16 weeks of ATI was significantly correlated with the week 22 VL ($P = 0.0246$; **Supplementary Fig. 7c**), indicating that CD4⁺ T cells harboring intact proviruses were contributing to the rebound in VL post ATI.

Furthermore, PTCs demonstrated significantly higher CD45RA^{int}RO^{int} T_{SCM} cell counts prior to ATI (week 6) compared to non-controllers ($P = 0.016$; **Fig. 4c**), indicating a role for these cells in control of VL. To provide an independent quantitative and qualitative assessment of the capacity of CCR5 gene-edited CD45RA^{int}RO^{int} T_{SCM} to differentiate into effector memory subsets, we tracked the persistence of CCR5 mutations unique to CD45RA^{int}RO^{int} T_{SCM} products in other memory cells post-infusion and post-ATI. We show that CD45RA^{int}RO^{int} T_{SCM}-unique CCR5 mutations were detected in other CD4⁺ memory subsets at week 6 (10.5%, 11% and 10.9% in T_{CM}, in T_{TM} and in T_{EM}, respectively) and were maintained at similar frequencies at week 22 (11.7%, 11.3% and 10.7% in T_{CM}, in T_{TM} and in T_{EM}, respectively; **Fig. 4d**), demonstrating the multipotency capacity of this subset. As T_{EM} cells have been shown to express the highest levels of CCR5 compared to other memory cells³⁹, maintenance of a subset of CCR5 gene-edited cells within the T_{EM} subset could lead to protection from *de novo* infection during ATI. To investigate this, we quantified the levels of CCR5 gene edited alleles in CD4⁺ T cell subsets during ATI and found that PTCs showed significantly higher frequencies of CCR5 gene-edited alleles at week 22 exclusively in the T_{EM} subset compared to non-controllers ($P = 0.029$; **Fig. 4e**). Moreover, we measured integrated HIV DNA levels in sorted CD4⁺ T cell subsets at baseline, and at weeks 6 and 22 post-infusion. Our results

indicate that the frequency of T_{EM} bearing integrated HIV DNA was significantly increased in non-controllers during ATI ($P = 0.0083$; **Fig. 4f**) but not in PTCs, with PTCs demonstrating significantly lower frequencies of infected T_{EM} cells at week 22 than non-controllers ($P = 0.0005$; **Fig. 4f**). Collectively, these results indicate that continuous replenishment of CCR5 gene-edited T_{EM} cells downstream of differentiation from their CD45RA^{int}RO^{int} T_{SCM} precursors confers greater protection from *de novo* infection of the T_{EM} subset in PTCs, consequently having an impact on control of active viral replication during ATI.

Long-term control of VL in a post-treatment controller that remained off ART for ~5 years post-infusion is associated with enhanced HIV-specific CD4⁺ and CD8⁺ T cell responses.

One of the SB-728-1101 trial participants (01-060) has remained off ART to this date since ART interruption at week 6 post-infusion (~5 years post infusion). This individual expressed the protective HLA-B57⁴⁰⁻⁴² allele and was heterozygote for the delta-32 CCR5 mutation (**Supplementary Table 8**), which may have contributed to his observed VL control. This individual has since been enrolled in the SCOPE cohort (study NCT00187512, conducted at the University of California, San Francisco) and has demonstrated control of VL at low but detectable levels (~100 copies/mL; **Fig.5a**). CD4⁺ T cell counts have decreased between the last time point (month 12) in the SB-728-1101 trial and his enrollment in the SCOPE cohort to ~200 cells/ μ l (**Fig. 5b**); however, this individual declined ART resumption, providing us with a unique opportunity to investigate the role of CCR5 gene-edited cells in partial VL control. Using the Pentamer Duplication assay, we observed higher levels of CCR5 gene-edited cells at 4 years post-

infusion compared to month 12 (~12% of CD4⁺ cells at year 4 compared to ~8% at year 1; **Fig 5c**), demonstrating the long-term maintenance of these cells as well as their enrichment compared to the non-edited cells in the presence of prolonged active virus replication. The frequency of CD4⁺ CD45RA^{int}RO^{int} T_{SCM} cells remained high post infusion up to month 12 (48% at week 6 and 38% at month 12; **Supplementary Fig. 8a,b**). However, the frequencies of CD4⁺ CD45RA^{int}RO^{int} T_{SCM} and T_{CM} progressively decreased post-ATI (from 40% at year 1 to 6.5% at year 4 and from 10.5% at year 1 to 3.6% at year 4, respectively) while that of CD4⁺ T_{EM} and CD8⁺ T_{EM} and T_{EMRA} progressively increased (**Supplementary Fig. 8b**), indicating a pull for differentiation into the T_{EM} and T_{EMRA} subsets in the presence of viremia. To further characterize the heterogeneity of the CD45RA^{int}RO^{int} subset, a 22-color Symphony stemness panel was performed on longitudinal samples from patient 01-60 including years 4 and 5 samples. Phenograph analysis identified 2 clusters that increased at early time points post infusion that remained detected long term (clusters 2 and 6, as well as a cluster that was uniquely up-regulated at years 4 and 5 (cluster 13; **Fig. 5d, e and Supplementary Fig. 8c**). Compared to the year 4/5 cluster, the persistent clusters expressed high levels of CCR7, CD27, CD95, CD127, TCF-7, and 4-1BB (**Fig. 5f and Supplementary Fig. 8d,e**), indicating that a subset of cells of the CD45RA^{int}RO^{int} phenotype represent long-lasting memory stem cells that can maintain expression of stemness markers during ongoing viral replication. Cells expressing CD45RA^{int}RO^{int} but down-regulating CCR7 and CD27 could represent cells transitioning to the T_{EM} phenotype during ongoing viral replication. To determine the impact of persistence of CD45RA^{int}RO^{int} T_{SCM} on CD4⁺ T cell helper function, longitudinal samples were stimulated with HIV gag peptide pools (**Fig. 5g,h**).

Increased frequency of polyfunctional HIV-specific CD4⁺ T cells (secreting high levels of TNF α and IFN γ) were detected at years 4 and 5 post infusion. Similarly, increased HIV-specific CD8⁺ T cell responses were also detected at years 4 and 5 post infusion (**Fig. 5i,j**). Responding CD4⁺ T cells included cells of T_{EM} phenotype as well as CD45RA^{int}RO^{int} CD27⁺CCR7⁺ cells, while responding CD8⁺ T cells included cells of T_{TM}, T_{EM}, and T_{EMRA} phenotypes (**Supplementary Fig. 9**). Concomitantly to increased HIV-specific T cell responses, a decrease in activation and exhaustion markers was observed in CD8⁺ T cells at years 4 and 5 post infusion (**Supplementary Fig. 10**). To determine how ongoing viral replication impacted the frequency of intact HIV DNA proviruses, the IPDA assay was performed on longitudinal samples. The frequency of intact provirus in purified CD4⁺ T cells remained low post ATI and increased between years 4 and 5 (from 6 to 127 copies per 10⁶ cells; **Fig. 5k**). The low level of VL at year 5 despite an increase in the frequency of intact provirus suggests a role for enhanced CD8⁺ HIV-specific immunity in maintaining control of viral replication.

Discussion

Previous studies of non-modified autologous T cell infusion in HIV-infected humans did not result in sustained CD4⁺ T cell reconstitution^{28,43,44} nor HIV reservoir decay, partly due to minimal persistence of infused cells⁴⁵ and their susceptibility to infection⁴⁶. Herein we show in two independent clinical trials that a single infusion of autologous CCR5 gene-edited cells is safe and well tolerated (see online discussion). Importantly, we found in the first study (SB-728-0902) that this intervention led to a sustained albeit quantitatively modest increase in CD4⁺ T cell numbers in individuals who failed to normalize their CD4⁺ T cell counts despite long-term effective ART, as well as to a

significant long-term decay of the estimated size of the total HIV reservoir, with a decrease in HIV DNA of over 1 log₁₀ copies per million cells in 4 of the 9 individuals. The decrease in HIV-infected cells using measures of HIV DNA is in sharp contrast to the very stable levels reported during long-term ART^{9,10,47} and in recent clinical trials using latency reversal agents⁴⁸⁻⁵² and was not a result of dilution of HIV-infected cells by the expansion of the infused product as the majority of the HIV decay was continuous over a span of 3 years. Our observed outcomes were associated with the expansion of a novel T_{SCM} subset, CD45RA^{int}RO^{int} T_{SCM}, that persisted long-term and comprised between 3 and 26% of CD4⁺ T cells 3-4 years post-infusion. The association of the expansion of this novel CD45RA^{int}RO^{int} T_{SCM} subset with improved control of HIV replication following ART interruption was demonstrated in the SB-728-1101 study. Our results highlighted the capacity of CD45RA^{int}RO^{int} T_{SCM} to differentiate into downstream short-lived memory T cells, by tracking ZFN-mediated mutations specific to CD45RA^{int}RO^{int} T_{SCM}, as well as the enhanced HIV-specific CD8⁺ T cell responses through cognate or non-cognate help as mechanisms associated with reservoir decay and virological control.

A CD45RA⁺CD45RO⁻CCR7⁺CD27⁺CD95⁺ T_{SCM}-like phenotype was reported following *in vitro* expansion of purified CD4⁺ and CD8⁺ naive T cells^{35,53} and *in vivo*³¹. This CD45RA⁺ T_{SCM} subset was shown to be endowed with self-renewal properties in serial transplantation experiments and long-term persistence (reviewed by Gattinoni et al⁵⁴). The CD45RA^{int}RO^{int} T_{SCM} subset described in both our clinical studies was present in the SB-728-T products and proliferated post-infusion as these cells significantly increased in cell frequencies. We demonstrated the importance of the longevity of CD45RA^{int}RO^{int}

T_{SCM} in the long-term persistence of infused CCR5 gene-edited cells. The capacity of CD45RA^{int}RO^{int} T_{SCM} for self-renewal was indicated by the presence of identical CCR5 mutations in the products and 3-4 years post-infusion and the maintenance of a significant fraction (~25%) of gene-edited cells in this subset 3-4 years post-infusion. The importance of this stem cell phenotype for increased CD4⁺ T cell numbers and HIV reservoir decay was confirmed as this subset was positively associated with both clinical outcomes, as well as with VL control.

Tracking of CCR5 ZFN-mediated mutations showed that CD45RA^{int}RO^{int} T_{SCM} cells have the capacity to differentiate into other memory subsets including T_{EM} (which included up to 3% of gene-edited alleles at years 3-4 post-infusion) defining this subset as a bona fide multipotent memory stem cell. Similar monitoring approaches of gene edited cells, using retroviral integration site (IS) analysis^{44,55-58}, have shown the differentiation of HSC to naive T cells and demonstrated the transition of CD45RA⁺ T_{SCM} to T_{CM} post-infusion of gene-edited cells. The potential of CD45RA^{int}RO^{int} T_{SCM} to form a diverse progeny was confirmed *in vitro* following TCR stimulation of this subset and phenotypic evaluation of proliferating cells. A multivariate model analysis of predictors of the HIV reservoir decline confirmed that long-term persistence of CD45RA^{int}RO^{int} T_{SCM} and differentiation of CCR5 gene-edited T_{SCM} into T_{EM} were associated with the reduction of HIV-infected cells. Our results suggest that the long-term decrease in HIV DNA post-infusion is a consequence of the continuous replacement of the pool of short lived T_{EM} cells, known to be preferentially infected by R5 tropic viruses⁵⁹, by the progeny of T_{SCM} cells that have low frequencies of HIV-infected cells and hence would not replenish the

viral reservoir; moreover, these cells harbor CCR5 gene-edited alleles which also makes their progeny resistant to infection.

CD45RA⁺ T_{SCM} have been shown to be susceptible to *in vitro* infection⁶⁰ and can constitute a stable source of latent HIV reservoir^{61,62}. A central hypothesis of our studies was that providing protection from HIV infection to a subset of CD4⁺ T cells would provide a global benefit and allow for reduction of the latent HIV reservoir and control of viral replication.

We recognized that the decay in HIV DNA in the SB-728-0902 trial might be due to the *ex vivo* expansion of both CCR5 gene edited and gene unmodified T_{SCM} cells within the infused products and that such cells would be protected *in vivo* by ART. Although several reports have described active viral replication during suppressive ART⁶³⁻⁶⁵, this remains a controversial subject^{66,67}. Nonetheless, inefficient drug penetrance, impaired immune function, immune privileged sites, and release of virus through clonal proliferation of infected cells^{16,68} have been suggested as mechanisms for viral persistence^{69,70}.

Consequently, CCR5 gene editing would offer a selective advantage in the presence of ongoing viral production in potential sanctuary sites. Nevertheless, our results from the SB-728-1101 trial demonstrate an increase in the frequency of CCR5 gene-edited cells in T_{EM} and a lack of an increase in integrated HIV DNA in that subset during active viral replication in PTCs, highlighting that differentiation of CCR5 gene-edited T_{SCM} into other memory subsets can lead to protection from *de novo* HIV infection. This was further confirmed by long-term monitoring of the pentamer duplication marker in the absence of ART in participant 01-060 where we saw an enrichment of CCR5 gene-edited cells between years 1 and 4 post-infusion. The increase in intact proviral DNA at year 5

confirms ongoing viral replication. Interestingly, this individual was heterozygote for the delta-32 CCR5 gene mutation which may have resulted in a greater probability of circulating bi-allelic CCR5 deleted cells, which would represent fully protected cells. The importance of limiting HIV infection in T_{SCM} (or T_{CM}) cells for the preservation of CD4⁺ T cell homeostasis was shown in non-human primates⁷¹ and viremic non-progressor HIV-infected individuals⁷². A follow-up randomized clinical trial (NCT03666871) with a larger cohort and a control arm will further evaluate the impact of CCR5 gene modification on T cell homeostasis and reservoir decay in the absence of ATI.

HIV-specific CD8⁺ T cell function has been implicated in the control of viral replication in elite controllers⁷³⁻⁷⁵ as well as post-ART controllers⁷⁶⁻⁷⁸. Moreover, numerous studies have shown that CD4⁺ T cell help is crucial for CD8⁺ T cell function^{79,80}. Monitoring T cell responses in participant 01-060 who controlled VL to levels ~100 copies/ml showed that HIV-specific CD4⁺ T cells producing TNF-α and IFN-γ were increased during ongoing ATI and coincided with an increase in HIV-specific CD8⁺ T cell polyfunctional responses. These results are in line with a recent study demonstrating that memory stem cell generation following vaccination in melanoma patients was associated with robust anti-tumor cell responses⁸¹. We also show in the SB-728-1101 study that HIV-specific CD8⁺ T cell polyfunctional responses increased post-ATI and correlated with HIV viral load and levels of integrated HIV DNA in T_{EM} cells. As only a subset of T_{CM}, T_{TM}, and T_{EM} cells contain CCR5 mutations, enhanced HIV-specific CD8⁺ T cell responses post-infusion is a mechanism that controls and potentially reduces the HIV reservoir during active viral replication.

In summary, our results indicate that infusion of CCR5 gene-edited cells provides a unique therapeutic intervention that improves T cell homeostasis and reduces the HIV reservoir. The less-invasive and autologous aspect of this therapy makes it more accessible than hematopoietic stem cell transplantation. Combining this approach with other interventions that enhance T_{SCM} proliferation and differentiation post-infusion might further improve outcomes.

Acknowledgements

We thank the study participants for their participation in this clinical trial. We thank Filipa Blasco Tavares, Vinicius Suzart, Victor Joo, Yuwei Zhang, Franck Dupuy, and Alessandra Noto for technical assistance, Michael Cartwright, Navnita Dutta, and Petra Stafova for assistance with Illumina microarrays, as well as Malika Aid, Abdelali Filali-Mouhim, Courtney Steel and Peter Wilkinson for bioinformatics support. We are grateful to Zhong He, Yu Shi, and Kim Kusser for flow cytometric cell sorting, and to Benjamin A. Youngblood, Mirko Paiardini and Joseph M. McCune for comments on the manuscript. The work was supported by the Foundation for AIDS Research (amFAR grants # 108549-53-RGRL and 108833-55-RGRL) and the Delaney AIDS Research Enterprise to cure HIV (DARE grant # AI096109).

Author contributions

J.L. recruited participants into the study. D.A. oversaw the clinical trial, clinical data management and clinical operations. S.D. wrote the protocol and oversaw the clinical study with D.A. J.Z., A.S., and G.L. designed and performed experiments and analyzed data under the guidance of R.-P.S. and D.A. A.R. performed statistical analysis of HIV reservoir decay under the guidance of G.M. and J.H. R.F., F.A.P., and N.C. designed and performed HIV reservoir measurements. S.F. performed bioinformatic analysis of CCR5 sequence tracking as well as multivariate model analysis. K.G., A.S., and M.A. performed bioinformatic analysis of gene array results. R.B. provided antibodies and helped with selection of Ab/fluorochrome combinations for multiparametric flow panels. G.P.S., G.C., and C.B. contributed to flow cytometry experiments and cell sorting. J.Z. and A.S. prepared the figures. J.Z., L.S., R.-P.S. and S.D. wrote the manuscript.

Author information

Microarray data was deposited at the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>), accession number GSE66214. Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Authors affiliated with Sangamo Therapeutics are employees and investigators are paid by Sangamo to perform the trial according to FDA approved good clinical trial practices. Correspondence and requests for materials should be addressed to R.-P.S. (rafick.sekaly@emory.edu).

Figure 1. Identification of a novel memory stem cell CD4⁺ T cell subset (CD45RA^{int}RO^{int} cells expressing CD95) that contributes to the persistence of CCR5 gene-edited T cells and total CD4⁺ T cells. **a**, Bar chart depicting the mean distribution of CD45RA⁺RO⁻R7⁺27⁺ cells (that include naïve and CD45RA⁺ T_{SCM}), T_{CM}, T_{TM}, T_{EM}, and CD45RA^{int}RO^{int} frequencies in CD4⁺ T cells at BL ($n = 9$), early (days 14-28; $n = 6$), mid (months 4-7, $n = 7$, and months 9-10, $n = 7$), late (months 11-12, $n = 9$), and long-term time points (year 3-4, $n = 9$) post-infusion. * $P < 0.05$, ** $P < 0.01$; Wilcoxon rank-sum test. **b**, Representative example of the gating strategy used to analyze the expression of CD58 and CD95, markers upregulated by memory stem cells, in CD45RA^{int}RO^{int} and CD45RA⁺RO⁻ subsets for participants 2-01 at BL and 6 months post SB-728-T infusion. **c**, Median frequency of the Pentamer Duplication marker per 10⁶ cells, a specific sequence tag that accounts for approximately 25% of CCR5 gene-edited cells, measured in sorted T_{CM}, T_{TM}, and T_{EM} memory subsets at d14-m4 ($n = 7$ for all 3 subsets), m6-8 ($n = 7, 7$, and 6, respectively), m11-12 ($n = 7, 7$, and 6, respectively), and year 3-4 ($n = 7, 7$, and 5, respectively), and in CD45RA⁺ T_{SCM} and CD45RA^{int}RO^{int} T_{SCM} at m9-10 ($n = 6$ and 5, respectively), m11-12 ($n = 3$ and 5, respectively), and year 3-4 ($n = 7$ and 8, respectively) post-infusion. N/A = not done due to limitations in availability of cryopreserved PBMCs. **d**, Distribution of the ZFN-mediated CCR5 mutations, determined by DNA sequencing, present uniquely in CD45RA^{int}CD45RO^{int} CCR7⁺CD27⁺ cells from SB-728-T products in CD4⁺ T cell subsets at year 3-4 ($n = 5$). Box shows median, first and third quartiles, and whiskers extend to a distance of 1.5*IQR. **e-g**, *In vitro* stimulation of purified CD45RA^{int}RO^{int} T_{SCM} sorted from year 3-4 samples ($n = 4$) post-infusion with DynaBeads Human T-activator CD3/CD28. Frequency of CD45RA^{int}RO^{int}, CD45RA⁺, and CD45RO⁺ cells in culture up to 6 days post stimulation in the different cycles of proliferation (**f**). Uniform Manifold Approximation and Projection (UMAP) dimension reduction analysis of flow cytometric phenotypic analysis of cells emerging from the CD45RA^{int}RO^{int} T_{SCM} subset post stimulation, with overlays of clusters 13 (which demonstrates lowest cycling at day 6) and 6 (which demonstrates highest cycling at day 6) (**g**). Frequency of clusters 13 and 6 for each proliferation cycle (1-5) and heatmap of their marker co-expression with red and blue squares indicating upregulation and down-regulation, respectively (**h**). Columns represent different cycles.

Figure 2. Decay of the HIV reservoir post SB-728-T infusion correlates with persistence of CCR5 gene-edited cells. **a**, Box-plot showing the frequency of cells harboring total HIV DNA per 10⁶ PBMCs at baseline (BL), year 1, and year 2 post-infusion (mean decay of -0.6 log₁₀, 95% confidence interval (CI) -1.19 to -0.006 at year 1 and -0.91 log₁₀, 95% confidence interval (CI) -1.71 to -0.11 at year 2). Box shows median, first and third quartiles, and whiskers extend to maximum and minimum values. Individual data points are shown for all 9 participants with colors corresponding to the different cohorts (cohort 1, 2 and 3 are shown in blue, green and red hues, respectively).

BL values for participants 1-01 and 1-02 were imputed as described in the online Methods. * $P < 0.05$; Wilcoxon rank-sum test. **b**, Frequencies of integrated HIV DNA copies per 10^6 purified $CD4^+$ T cells are shown at BL and year 2-3 (long-term follow up). Participants in cohorts 1, 2 and 3 are shown in blue, green and red symbols, respectively. * $P < 0.05$; Wilcoxon rank-sum test. **c**, Correlation between the frequencies of integrated HIV DNA in $CD4^+$ T cells and total HIV provirus assessed by the IDPA assay. **d**, 3-D scatter plot showing the change in the frequency of PBMCs harboring total HIV DNA post-infusion (Ratio of $\log_{10}$ values at day 720 over day 0) as a function of $CD45RA^{int}RO^{int} T_{SCM}$ cell counts at years 3-4 (z-axis), $\log_{10}$ Pentamer Duplication levels in $CD45RA^{int}RO^{int} T_{SCM}$ at years 3-4 (x-axis), and the ratio of the frequency of Pentamer Duplication in $CD45RA^{int}RO^{int} T_{SCM}$ by the frequency of Pentamer Duplication in T_{EM} at years 3-4 (y-axis). These features, together with $\log_{10}$ Pentamer Duplication levels in $CD45RA^{int}RO^{int} T_{SCM}$ at year 1 (not plotted), were determined as the best predictors of reservoir decay by a sparse linear multivariate model. The multivariate regression model to predict the reservoir decay contained the following features (see Supplementary Table 5): $CD45RA^{int}RO^{int} T_{SCM}$ cell counts at years 3-4, the frequency of Pentamer Duplication in $CD45RA^{int}RO^{int} T_{SCM}$ at multiple time points, the Ratio Pentamer Duplication $CD45RA^{int}RO^{int} T_{SCM}/T_{EM}$ at month 12 and years 3-4, the number of shared mutations between $CD45RA^{int}RO^{int} T_{SCM}$ and T_{EM} at years 3-4. Each dot in the scatter plot corresponds to a participant, with dot size proportional to the HIV DNA day 720/BL ratio, with a greater decay (i.e., smaller ratio) symbolized by a greater dot size (adjusted $r^2 = 0.99$, F-test: $P = 0.0008$). **e**, Heatmap representing pathways expressed in $CD45RA^{int}RO^{int} T_{SCM}$ that were associated with HIV reservoir decay (ratio of $\log_{10}$ HIV DNA values at day 720 over day 0; $P = 0.19$), with the range of the outcome presented as legend below the heatmap. Rows represent pathways and columns represent samples. Red and blue correspond to up- and down-regulated pathways respectively. The range of HIV reservoir decay is presented as legends at the bottom of the heatmap.

Figure 3. $CD45RA^{int}RO^{int} T_{SCM}$ are distinct from previously identified $CD45RA^+ T_{SCM}$ cells and constitute a novel T_{SCM} subset with features of quiescent uncommitted and long-lived memory cells. **a**, Volcano plot of genes differentially expressed by $CD45RA^+ T_{SCM}$ and $CD45RA^{int}RO^{int} T_{SCM}$ at year 3-4 ($n = 7$) post-infusion. **b**, SLEA plot of selected pathways significantly enriched in genes induced or repressed in $CD45RA^{int}RO^{int} T_{SCM}$ compared to $CD45RA^+ T_{SCM}$ at year 3-4 ($n = 7$) post-infusion. Scale represents SLEA score with red and blue squares indicating positive and negative enrichment respectively. Columns represent $CD45RA^{int}RO^{int} T_{SCM}$ and $CD45RA^+ T_{SCM}$ subsets. **c**, Volcano plots illustrating the expression of the transcription factors T-bet, Eomes, ROR γ t, and GATA-3 in $CD4^+$ T cell subsets at year 3-4 post-infusion ($n = 7$). * $P < 0.05$; Wilcoxon rank-sum test. **d**, Uniform Manifold Approximation and Projection (UMAP) dimension reduction analysis of flow cytometric phenotypic analysis of PBMCs at years 3-4 post infusion ($n = 6$) in response to stimulation with DynaBeads Human T-

activator CD3/CD28. **e**, Frequency of two clusters (11 and 13) uniquely up-regulated post-stimulation and their subset distribution. **f**, Heatmap depicting the expression of markers associated with memory T cell phenotypes (CD45RA, CCR7, CD27, CD45RO, and CD95) and effector cytokines (IFN- γ , IL-2, MIP-1 α , and TNF- α) of clusters 11 and 13, with a naïve T cell cluster (14) used as control. **g**, MFI levels of TNF- α , IL-2, MIP-1 α , and IFN- γ shown for naïve T cells (cluster 14), T_{CM}, and CD45RA^{int}RO^{int} T_{SCM} (cluster 13) and T_{EM} (cluster 11).

Figure 4. CCR5 gene-edited CD45RA^{int}RO^{int} T_{SCM} prior to ATI, levels of CCR5 gene-edited T_{EM} and HIV-specific CD8+ T cell polyfunctionality during ATI correlate with control of viral load and lower reseeded of the T_{EM} HIV reservoir. a, Plot depicting the viral load (VL) values at week 22 (equivalent to 16 weeks of ATI) and the historic pre-ART viral set point values obtained from participants' charts. Participants with extended ATI and a reduction of week 22 VL compared to the historic pre-ART VL greater than 0.5 log are shown in red (post-treatment virologic controllers; PTCs). *P* value of Wilcoxon rank-sum test is shown. VL for all participants post-ATI are shown in Supplementary Table 9. **b**, The HIV reservoir quantified in purified CD4⁺ T cells (integrated HIV DNA, total and intact proviral HIV DNA) after 16 weeks of ATI is shown for non-controllers (black) and PTCs (red). Lines depict means. Virological and immunological assays were performed for participants of cohort 3-5 for whom cryopreserved cells were available for analysis. **c**, Violin plot representing the frequency of CD45RA^{int}RO^{int} T_{SCM} cell counts prior to ATI (week 6) in non-controllers (black) and PTCs (red). **d**, Box-plot showing the percent of ZFN-induced CCR5 mutations present uniquely in CD45RA^{int}CD45RO^{int} T_{SCM} in SB-728-T products that are detected in CD4⁺ T cell subsets at weeks 6 and 22 post-infusion (*n* = 7). Box shows median, first and third quartiles, and whiskers extend to a distance of 1.5*IQR. Outliers are shown as dots. **e**, Violin plot representing the frequency of CCR5 gene edited alleles in T_{EM} at week 22 in non-controllers (black) and PTCs (red) in participants of cohort 3-5. **f**, Violin plot representing the frequency of integrated HIV DNA within T_{EM} cells at BL, week 6 and week 22 post-infusion (*n* = 7) in non-controllers (black) and PTCs (red) in participants of cohort 3-5. * *P* < 0.05.

Figure 4. Long term control of viral load for up to 5 years post infusion in participant 01-060. Participant 01-060's VL (**a**), CD4+ T cell counts (**b**), and Pentamer Duplication levels normalized to CD4+ T cells (**c**) are shown post-infusion, post-ATI, and during long term follow up. The years 4 and 5 time point visits are highlighted in red and orange, respectively. **d**, Uniform Manifold Approximation and Projection (UMAP) dimension reduction analysis of flow cytometry phenotypic analysis of the CD45RA^{int}RO^{int} T_{SCM} subset in participant 01-060, with overlays of clusters 2 and 6 (which increased by week 2 post infusion and remain above BL) and 13 (which increased at years 4 and 5) **e**, Frequency of clusters 2, 6 and 13 in total CD4+ T cells. **f**, Expression

of markers upregulated in memory stem cells (CD27, CCR7, CD127, TCF-6, and 41BB) in clusters 2, 6 and 13. **g**, Dot plot of CD4⁺ T cells producing both IFN- γ and TNF- α cytokines post a 6-hour gag peptide pool stimulation in longitudinal samples from participant 01-060 (shown for week 2 and year 5). **h**, The frequency of CD4⁺ T cells producing both IFN- γ and TNF- α cytokines post a 6-hour gag peptide pool stimulation in longitudinal samples from participant 01-060 is overlaid with VL levels post ATI. **i**, Dot plot of CD8⁺ T cells producing both IFN- γ and TNF- α cytokines post a 6-hour gag peptide pool stimulation in longitudinal samples from participant 01-060 (shown for week 2 and year 5). **j**, The frequency of CD8⁺ T cells producing both IFN- γ and TNF- α cytokines post a 6-hour gag peptide (GAGa ad GAGb) pool stimulation (green and orange bars, respectively; right Y axis) in longitudinal samples from participant 01-060 is overlaid with VL levels post ATI. **k**, Frequency of intact provirus as measured by the IPDA assay (purple bars; right Y axis) in longitudinal samples from participant 01-060 is overlaid with VL levels (black).

Methods

Study design. The SB-728-0902 clinical trial is a Phase 1, open label, uncontrolled, nonrandomized study of individuals with chronic HIV infection treated with ART (ClinicalTrials.gov # NCT01044654). The study was sponsored by Sangamo Therapeutics and was conducted at two centers in the United States between December 2009 and April 2014. The primary objective of the study was to assess the safety and tolerability of ascending dose of autologous CD4⁺ enriched T cells edited at the CCR5 gene by ZFNs (SB-728-T cells). Secondary objectives included the assessment of increases in CD4⁺ T cell counts, long-term persistence of CCR5 gene-edited cells, homing to gut mucosa, and the effects on HIV viral persistence (HIV RNA and proviral DNA). A total of 9 participants were enrolled into three ascending dose cohorts (Cohort 1 received 10 x 10⁹ SB-728-T, cohort 2 received 20 x 10⁹ SB-728-T, and cohort 3 received 20 x 10⁹ SB-728-T), with three participants in each cohort (Supplementary Table 1). All participants were followed weekly for the initial 4 weeks and then monthly thereafter for one year, after which they were enrolled in a three-year safety study. Participant 1-01 underwent a treatment interruption between months 12 and 22; viral load measurements are listed in Supplementary Tables 10 and 11 and ART regimens are detailed in Supplementary Table 13.

The SB-728-1101 clinical trial is a Phase 1, open label, uncontrolled, nonrandomized study of individuals with chronic HIV infection treated with ART (ClinicalTrials.gov #NCT01543152). The study was sponsored by Sangamo Therapeutics and was conducted at 12 centers in the United States between March 2012 and January 2017. The primary objective of the study was to evaluate the safety and tolerability of escalating doses of cyclophosphamide (CTX) pre-treatment to promote CD4⁺ T cell expansion after administration of a single dose of SB-728-T cells. Participants received CTX at doses of 0.1 (Cohort 1, $n = 2$), 0.5 (Cohort 2, $n = 4$), 1.0 (Cohort 3, $n = 3$), 1.5 (Cohort 5, $n = 3$) and 2.0 g/m² (Cohort 4, $n = 3$) one day before infusion of SB-728-T cells (Supplementary Table 14). Participants subsequently received between ~10 to 40 billion SB-728-T cells (Supplementary Table 8). All participants were followed weekly for the initial 4 weeks, bi-monthly until week 14, monthly until week 22, and then every 2 months until month 12. ART was discontinued 6 weeks after SB-728-T infusion for a period of 16 weeks (Supplementary Fig. 7b). Secondary objectives included the evaluation of the effect of SB-728-T cells on plasma HIV-1 RNA levels following ART interruption. During the treatment interruption, ART was reinstituted in participants whose CD4⁺ T cell counts dropped to <500 cells/ μ L and/or whose HIV-RNA increased to >100,000 copies/mL on three consecutive weekly measurements. Following completion of the 1-year study, participants were enrolled in a 3-year long-term safety study. Adverse events are summarized in the on-line discussion.

The final clinical protocol, amendments, and consent documents were reviewed and approved by the NIH Recombinant DNA Advisory committee, as well as institutional review board and institutional biosafety committee (as required) at each study center. All participants provided written informed consent.

Enrollment criteria.

SB-728-0902 Trial: Eligible participants were 18 years of age or older and were chronically infected with HIV, as documented by ELISA. Participants were on long-term stable ART and aviremic (undetectable HIV RNA for at least one year prior to enrollment), with CD4⁺ T cell counts between 200 and 500 cell/ μ L (immune non-responders; Supplementary Table 1) and had adequate venous access and no contraindications to leukapheresis. The key exclusion criteria included a SNP at the CCR5 ZFN target region, current or prior AIDS diagnosis, receiving therapy with maraviroc or immunosuppressives, and hepatitis B or hepatitis C co-infection.

SB-728-1101 Trial: Eligible participants were 18 years of age or older and were chronically infected with HIV, as documented by ELISA. Participants were aviremic on stable ART with CD4⁺ T cell counts >500/ μ L, had R5 tropic HIV, and willing to discontinue current ART during the treatment interruption (Supplementary Table 14). The key exclusion criteria included adenoviral neutralizing antibodies >40, a SNP at the CCR5 ZFN target region, current or prior AIDS diagnosis, receiving therapy with maraviroc or immunosuppressives, and hepatitis B or hepatitis C co-infection.

Cell manufacture and infusion. Production of SB-728-T cells was previously described^{29,82}. Briefly, participants underwent a 10L leukapheresis to collect, enrich, modify and expand autologous CD4⁺ T cells. Manufacturing of the SB-728-T products includes a T cell activation step (with anti-CD3/anti-CD28-coated magnetic beads) and an IL-2 expansion step²⁹. ARV drugs (Ritavir and Norvir with or without Fuzeon) were added during manufacture to inhibit de novo infection of CD4⁺ T cells. SB-728-T refers to autologous CD4⁺ enriched T cells that have been transduced *ex vivo* with SB-728, a replication deficient recombinant Ad5/35 viral vector encoding the CCR5 specific ZFNs (SBS8196z and SBS8267), that includes a mixture of gene-edited and non-edited cells. Expression of CCR5-specific ZFNs induces a double stranded break in the cell's DNA which is repaired by cellular machinery leading to random sequence insertions or deletions (indels) in ~25% of transduced cells. These indels disrupt the CCR5 coding sequence leading to frameshift mutation and termination of protein expression.

Infusion of SB-728-T was conducted employing a standard intravenous infusion method common to all adoptive cell transfer protocols. Participants were pre-medicated with acetaminophen 650 mg P.O. and 25-50 mg Benadryl P.O. approximately 1 hour prior to infusion. Cryopreserved SB-728-T products were thawed bed-side and infused via the intravenous route using the Smartsite gravity set.

Cryopreserved peripheral blood mononuclear cells (PBMCs) samples.

SB-728-0902: PBMCs were prepared from whole blood by ficoll-hypaque density sedimentation and used cryopreserved in 10% dimethyl sulfoxide (DMSO) and 90% FBS. Availability of cryopreserved samples at different time points varied between participants; consequently, time points were grouped into early (14-28 days), mid (4-7 months or 9-10 months), late (11-12 months), and long-term (2-3 or 3-4 years) post-infusion time points. Baseline samples included cryopreserved PBMCs from the initial leukapheresis (2-3 months before infusion) as well as from a small volume blood draw 1-2 weeks before infusion. PBMCs from participants 1-01, 1-02, and 1-03 were not cryopreserved until months 6 or 8 post-infusion. Most participants agreed to a large volume blood draw ($n = 9$, year 2-3) and a leukapheresis ($n = 7$, year 3-4) during the long-term follow-up period to allow for assays requiring large amounts of cells, such as CCR5 sequencing, integrated HIV DNA quantification, and gene arrays in sorted CD4⁺ T cell subsets. For certain assays, including flow cytometry phenotyping, baseline samples for only 6 participants remained available. Manufacturing samples (SB-728-T products) were also available for all participants.

SB-728-1101: Clinical measures (CD4, CD8 counts, viral load (VL), and the Pentamer Duplication marker) were performed at every time point. Availability of cryopreserved PBMCs at baseline and pre-ATI were not available for Cohorts 1 and 2 participants; consequently immunological (T cell phenotyping, CCR5 DNA sequencing of ZFN mediated mutations in sorted CD4⁺ subsets) and virological (Integrated HIV DNA) measurements were only performed in participants from Cohorts 3-5. Baseline samples included cryopreserved PBMCs from the initial leukapheresis (2-3 months before infusion) as well as from a small volume blood drawn 1-2 weeks before infusion. Manufacturing samples (SB-728-T products) were also available for Cohorts 3-5 participants.

Rectal and lymph node biopsies. Rectal biopsies were performed for participants of the SB-928-0902 trial at baseline, day 14, month 3, 6 and 12 (n varied between 3 and 9 participants per time point). Mucosal mononuclear cells were isolated from sigmoid colon biopsies obtained by endoscopy via a combination of collagenase digestion and teasing with 18G needles. Inguinal lymph nodes were biopsied from 3 volunteers at one time point (between 9 and 18 months) post-SB-728-T infusion. Tissues were processed into single cells as described in Anton et al⁸³ and genomic DNA were isolated for assessment of CCR5 gene modifications.

Quantification of CCR5 gene modification in SB-728-T products using Cel-I. The Cel-I nuclease specifically cleaves DNA duplexes at the sites of distortions created by either bulges or mismatches in the double helical DNA structure. We have adapted protocols using this enzyme for quantification of minor indels typically induced by ZFN-

mediated gene modifications. Briefly, the genomic region of interest (CCR5) is PCR amplified, the PCR product is denatured and then allowed to re-anneal to permit wild type and non-homologous end joining-edited alleles to re-anneal together and create hetero-duplexes. The re-annealed PCR products are then digested with the Cel-I nuclease to cut the PCR-amplified DNA at the site of mismatches. Subsequently, the level of ZFN-mediated gene modification can be quantified by determining the ratio of the uncleaved parental fragment to the two lower migrating cleaved products.

Quantification of CCR5 gene-edited CD4⁺ T cells by Polymerase Chain Reaction.

ZFN-mediated gene modification can generate a wide range of frame-shift mutations to disrupt the CCR5 gene locus. A PCR-based assay was developed to measure the acquisition of a unique duplication of 5-nucleotide (Pentamer) DNA sequence, CTGAT, at the ZFN cleavage site in approximately 25% of the gene-edited alleles²⁹. Genomic DNA (gDNA) was extracted from PBMCs using a commercially available kit (Masterpure DNA Purification kit, Epicenter, Madison, WI). A standard PCR was performed with 5µg of gDNA to amplify a 1.1 kb region that contains CCR5 gene modifications. This 1.1 kb amplicon is subsequently evaluated with the two independent qPCRs, one specific for the Pentamer Duplication- CCR5 gene-edited allele (by using a primer that contains the Pentamer Duplication), and a second that amplifies all CCR5 alleles. The ratio of Pentamer Duplication-specific templates and the total number of CCR5 alleles yields Pentamer Duplications per 1 million PBMCs. The assay has a sensitivity of one CCR5 gene-edited allele per 10⁵ total CCR5 alleles. As the Pentamer Duplication markers represents ~25% of ZFN-mediated gene modifications, the total frequency of CCR5 gene-edited cells in PBMCs was estimated by multiplying the frequency of Pentamer Duplication gene-edited cells by 4.

Estimation of expansion of SB-728-T post-infusion. The level of CCR5 gene-edited alleles present in a participant post-infusion relative to the amount infused can be estimated using the measured values of CCR5 modification by the Pentamer Duplication marker and CD4⁺ cell count with the assumptions; 1) blood volume is 4.7 liters, 2) approximately 2.5% of all CD4⁺ T cells are found in the periphery⁸⁴ and 3) SB-728-T products distribution is similar to endogenous CD4⁺ T cells (levels of CCR5 modification in CD4⁺ T cells from the sigmoid and inguinal nodes are similar to that in the periphery, Supplementary Fig. 4).

Engraftment of SB-728-T

$$= \frac{(\% \text{ CD4 with the Pentamer Duplication marker}) \times (\text{CD4 count}) \times (\text{blood volume}) \times \frac{1}{2.5\%}}{(\% \text{ SB-728-T with the Pentamer Duplication marker}) \times (\text{Total SB-728-T infused})}$$

Quantification of CCR5 gene modification via next-generation sequencing/MiSeq.

The locus of interest (ZFN binding sites in CCR5) was PCR amplified from genomic

DNA, and the levels of modification at each locus were determined by paired-end deep sequencing on an Illumina MiSeq sequencer. Paired sequences were merged via SeqPrep (John St. John, <https://github.com/jstjohn/SeqPrep>, unpublished). A Needleman-Wunsch alignment was performed between the target amplicon genomic region and the obtained Illumina sequence to map indels⁸⁵. CCR5 sequencing was performed in sorted CD4⁺ T cell subsets from SB-728-0902 participants in SB-728-T products ($n = 9$) and year 3-4 samples ($n = 8$) as well as from SB-728-1101 Cohorts 3-5 participants in SB-728-T products ($n = 7$) and weeks 6 and 22 samples ($n = 7$). Perez *et al.*, had shown that approximately 30% of CCR5 gene modifications were bi-allelic²⁹. For simplicity, CCR5 gene-edited memory subset cell counts were estimated by multiplying each memory subset cell count by the frequency of CCR5 gene-edited alleles within each memory subset as determined by CCR5 DNA-Seq, thereby assuming that one gene-edited allele is equivalent to one cell.

Cell tracking of CCR5 gene-edited CD45RA^{int}RO^{int} T_{SCM} post SB-728-T infusion.

Sequencing of CCR5 ZFN-mediated mutations in sorted CD4⁺ T cell subsets was used to track differentiation of CD45RA^{int}RO^{int} T_{SCM} cells post-infusion. First, wild type CCR5 (amplicon) and sequences detected in only 1 of the samples sequenced were excluded from further analysis (~80% of unique CCR5 sequences). Then, for each participant, we identified the sequences expressed only in CD45RA^{int}RO^{int} T_{SCM} cells in SB-728-T products and then analyzed their distribution in CD4⁺ T cell memory subsets at year 3-4 samples (SB-728-0902) or weeks 6 and 22 samples (SB-728-1101).

Flow cytometry analysis.

Surface staining. Two surface panels were run for longitudinal analysis of CD4⁺ T cell distribution in SB-728-T products and post-infusion, including a T_{SCM} panel (Figs. 1a,c and 4c, and Supplementary Fig. 3), using previously titrated monoclonal antibodies summarized in Supplementary Table 8. Thawed PBMCs (1-2 million cells) were labelled for 30 minutes in the dark at 4°C, washed with staining buffer (PBS, 2% FBS), fixed with 2% FA (Sigma Aldrich) for 15 min at 22°C, and resuspended in staining buffer for acquisition. A minimum of 100,000 live cells were acquired within 24hrs using a BD LSR-II or BD LSRFortessa™ cell analyzer and analyzed using the FlowJo version 9 software (TreeStar, Ashland, OR). Longitudinal samples from each participant were stained in the same batch run and a common set of control cells (obtained from an independent ART-treated HIV-infected donor) was stained when samples from different participants were stained in separate runs.

Intracellular Cytokine Staining (ICS). A transcription factor panel (Supplementary Table 8) was used to determine Th-lineage in CD4⁺ T cell subsets in the SB-728-0902 study (Fig. 3c). Thawed PBMCs were labelled with surface antibodies for 30 minutes at 4°C prior to fixation with eBioscience's Foxp3 Fixation/Permeabilization buffer for 30

minutes at 4°C. Cells were then labelled with the intracellular antibodies for 30 minutes at 22°C in eBioscience's Foxp3 permeabilization buffer, resuspended in staining buffer (PBS, 2% FBS), and immediately acquired using a BD LSRFortessa™ flow cytometer. An ICS panel (Supplementary Table 8) was used to quantify effector cytokine production in CD4⁺ T cell subsets following T cell stimulation (Fig. 3d-g) or gag peptide pool stimulation (Fig. 4g-j and Supplementary Fig. 9). Cells were labelled with surface antibodies, and permeabilised with Perm buffer (BD Bioscience) after which cells were stained intracellularly prior to fixation with 2% formaldehyde. Cells were acquired within 24 hours using a BD LSR-II or BD LSRFortessa™. A minimum of 500,000 live events was acquired. Longitudinal samples were stained in the same batch run. Cells were analyzed using FlowJo version 10.

Additional intracellular panels were used to further characterize the stemness of the CD45RA^{int}RO^{int} subset and CD8⁺ T cell activation and exhaustion (Fig 4d-f and Supplementary Fig. 10) in longitudinal samples from participant 01-060 (Supplementary Table 8).

Cell proliferation and stemness/effector phenotype progression of *in vitro* stimulated CD45RA^{int}RO^{int} T_{SCM} (Fig. 1e-h and Supplementary Fig. 4) was determined by measuring the progressive dilution of CellTrace Violet (Thermo Fisher Scientific) combined with an intracellular panel (Supplementary Table 8).

Uniform Manifold Approximation and Projection (UMAP) Analysis of flow cytometry panels. Live CD3⁺CD4⁺ cells (Figs. 1e-h, 3d-g, and Supplementary Fig. 4), live CD4⁺CD45RA^{int}RO^{int} cells (Fig. 5d-f and Supplementary Fig. 8c-e), or live CD3⁺CD4⁺CD8⁺ T cells (Supplementary Fig. 10) were gated and exported for unbiased clustering analyses. For these panels, projection of the density of cells expressing markers of interest were visualized/plotted on a 2-dimensional UMAP (<https://arxiv.org/abs/1802.03426>, <https://github.com/lmcinnes/umap>). Clusters of cells were identified using the RPhenograph package (<https://github.com/jacoblevine/PhenoGraph>) after concatenating all samples per panel and bi-exponentially transforming each marker. The K value, indicating the number of nearest neighbors, was set to 60. Data were visualized using FlowJo version 10 and R for heatmaps highlighting differences in MFI for each marker per cluster.

Cell culture and stimulation conditions. Thawed PBMCs were rested in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin–streptomycin for 12 hours. To induce cytokine production, 2 million cells were activated with dynabeads human T activator CD3/CD28 at a 1:1 bead to cell ratio (Thermo Fisher Scientific), Staphylococcal enterotoxin B (SEB; 1µg/mL) (Toxin Technology), Phorbol myristate acetate (PMA) (100 ng/mL) and Ionomycin (1µg/mL) (both from Sigma Aldrich), or only complete media (mock) for 6 hours in the presence of Brefeldin A (5µg/mL) (Sigma Aldrich). In a

separate experiment, thawed PBMCs were rested for 12 hours prior to stimulation of 2 million cells with either gag peptide pool (GAGa and b pools; 1µg/mL; NIH AIDS reagent program), Staphylococcal enterotoxin B (SEB; 1µg/mL) (Toxin Technology), CEF control peptide pool (SB-728-1101 study only: 1µg/mL; NIH AIDS reagent program), or only complete media (mock) for 6 hours in the presence of Brefeldin A (5µg/mL) (Sigma Aldrich).

HIV DNA in PBMCs, total and sorted CD4⁺ T cell subsets. Total HIV DNA in PBMCs was measured by droplet digital polymerase chain reaction. In brief, genomic DNA (gDNA) was extracted from PBMCs using a commercially available kit (Masterpure DNA Purification kit, Epicenter, Madison, WI). 2 µg of gDNA was digested with the restriction enzyme DdeI at 37°C for 1 hour. PCR droplets were prepared according to manufacturer's recommendations. Briefly, a 20µL of multiplex PCR mixture is prepared by mixing 250 or 500 ng of the digested gDNA with the ddPCR™ 2x Master Mix and two Taqman primer/probe sets. The Taqman primer/probe sets amplify a conserved region in gag (as described by Palmer *et. al.*, HIV gag forward CATGTTTTTCAGCATTATCAGAAGGA, HIV gag reverse TGCTTGATGTCCCCCACT, HIV gag probe, FAM-CCACCCCA CAAGATTTAAACACCATGCTAA-BHQ) and the human Ribonuclease P protein subunit p30 (RPP30 forward GATTGGACCTGCGAGCG, RPP30 reverse GCGGCTGTCTCCACAAGT, RPP30 probe VIC-CTGACCTGAAGGCTCT-MGB-BHQ)⁸⁶. PCR droplets were generated in a DG8™ cartridge using the QX-100 droplet generator, where each 20µL PCR mixture was partitioned into approximately 15,000 nano-liter size droplets. PCR droplets were transferred into a 96-well PCR plate and sealed with foil. Standard PCR was performed with a Bio-Rad C1000 Thermal Cycler (95°C (60sec), 40 cycles of 94°C (30sec)/ 60°C (60sec), 98°C (600 sec)). HIV DNA copy number was evaluated using the QX-100 Droplet Digital PCR system (Bio-Rad, Hercules, CA). The PCR-positive and PCR-negative droplets for HIV gag and RPP30 were determined and template concentrations were calculated by Poisson analysis. HIV copy number was determined by normalizing HIV gag concentration to RPP30 concentration⁸⁶. Integrated DNA was measured as previously described⁸⁷ in purified CD4⁺ T cells from SB-728-0902 participants at baseline, in SB-728-T products, year 2-3 samples (*n* = 9) and in sorted CD4⁺ T cell subsets in SB-728-T products and year 3-4 samples (*n* = 8). Integrated DNA was also measured in purified CD4⁺ T cells as well as sorted CD4⁺ T cell subsets from SB-728-1101 Cohorts 3-5 participants in baseline, weeks 2-6 and 14-22 samples (*n* = 8).

HIV Tropism Assay. HIV Tropism was evaluated using the commercial Trofile® DNA assay (Monogram BioSciences/ LabCorp, South San Francisco, CA). Viral envelope

DNA sequence was extracted from PBMCs. HIV tropism is determined using a cell-based transduction assay where HIV env protein sequences are amplified from PBMC samples, subcloned as a library, packaged into lentiviral vectors, and evaluated using co-receptor restricted cell lines.

T cell Receptor (TCR) Repertoire. TCR repertoire analysis was performed with the immunoSEQ assay (Adaptive Biotechnologies, Seattle, WA). The immunoSEQ method amplifies rearranged TCR CDR3 sequences by multiplex PCR to explore all V β and J β combinations from isolated genomic DNA and uses high-throughput sequencing technology to sequence TCR CDR3 chains to determine the composition of various T cell clones within each sample. TCR diversity is assessed using the Shannon entropy index^{33,88}, which accounts for both the number of unique clones (richness) and clone distribution (evenness) of the TCR V β CDR3 sequences present in each sample. A larger Shannon entropy index reflects a more diverse distribution of the TCR V β CDR3 sequences.

Cell sorting. For quantification of the Pentamer Duplication maker, CCR5 gene-edited alleles using DNA-Seq, and levels of integrated HIV DNA within CD4⁺ T cell subsets, CD4⁺ T cells were first isolated from PBMCs by negative magnetic selection (StemCell), and then surface stained with CD3 Alexa 700 (clone UCHT1), CD95 PE-Cy7 (clone DX2), CD58 PE (clone 1C3), CD127 BV421 (clone HIL-7R-M21), CD28 APC (clone CD28.2), CD14 V500 (clone M5E2) (all from BD Biosciences), CD4 Qdot 605 (clone S3.5) (Invitrogen), CD27 APCe780 (clone O323) (eBioscience), CD45RA BV 650 (clone HI100), CD45RO PerCPe710 (clone UCHL1), CD19 BV 510 (clone H1B19) (all from Biolegend), CCR7 FITC (clone 150503) (R&D), aqua fluorescent reactive dye (Invitrogen), and CD8 PerCP (clone SK1) from Biologend (SB-728-0902 study) or CD8 BV711 (clone RPA-T8) from BD (SB-728-1101 study). Up to 200,000 total CD4⁺ T cells as well as CD4⁺ T cell subsets were then sorted with the FACS Aria (Becton Dickinson) and stored as dry pellets at -80°C until analysis. For gene array analysis of CD4⁺ T cell subsets in the SB-728-0902 study, 10,000 sorted cells (naïve, CD45RA⁺ T_{SCM}, CD45RA^{int}RO^{int} T_{SCM}, T_{CM}, and T_{EM}) were collected directly into RNase-free 1.5mL eppendorf tubes containing 500 μ L of RLT buffer with 1% β -mercaptoethanol and stored at -80°C until analysis.

Gene Microarray and Analyses. Sorted CD4⁺ memory subsets from year 3-4 samples were sorted into RLT buffer as described above and included naïve, CD45RA⁺ T_{SCM}, CD45RA^{int}RO^{int} T_{SCM}, T_{CM}, and T_{EM} cells. Sorted cells were lysed for RNA extraction as per manufacturer's instructions (Qiagen, Valencia, CA). T7 oligo(dT) primed reverse transcription reactions were performed followed by *in vitro* transcription. These products underwent a second round of amplification (MessageAmp II aRNA Amplification kit by

Life Technologies) yielding biotin-labeled aRNAs which were hybridized to the Illumina Human HT-12 version 4 Expression BeadChip according to the manufacturer's instructions and quantified using an Illumina iScan System.

Analysis of gene array output data was conducted using the R statistical language (<http://www.r-project.org/>)⁸⁹ and the Linear Models for Microarray Data (LIMMA) statistical package⁹⁰ from Bioconductor⁹¹. Briefly, scanned array images were inspected for artifacts and unusual signal distribution within chips, and arrays with low overall intensity or variability were removed from analysis. Diagnostic plots such as density plots, box plots, and heatmaps of between-array distances were used to assess hybridization quality across chips. Intensities were log2 transformed before being normalized using the quantile normalization method⁹². Probes that did not map to annotated RefSeq genes and control probes were removed. The LIMMA package was used to fit a linear model to each probe and perform a moderated Student's *t*-test to assess the difference in gene expression level between the different subsets. For data mining and functional analyses, genes that satisfied a *P* value < 0.05 were selected. The proportions of false positives were controlled using the Benjamini and Hochberg method⁹³. All microarray data have been deposited in GEO under accession number GSE66214.

We performed Gene Set Enrichment Analysis (GSEA)⁹⁴ using MSigDB (<http://software.broadinstitute.org/gsea/msigdb/>) curated gene sets to identify enriched biological pathways that are modulated in CD45RA^{int}RO^{int} T_{SCM} compared to the CD45RA⁺ T_{SCM} subset. GSEA is a statistical method to determine whether members of a particular gene set preferentially occur toward the top or bottom of a ranked-ordered gene list where genes are ranked by the strength of their association with the outcome of interest. More specifically, GSEA calculates an enrichment score (NES) that reflects the degree to which a set of genes is overrepresented among genes differently expressed. The significance of an observed NES is obtained by permutation testing: resorting the gene list to determine how often an observed NES occurs by chance. Leading Edge analysis is performed to examine the particular genes of a gene set contributing the most to the enrichment. We discarded gene sets with a false discovery rate (FDR) > 25% and a nominal *P* value > 0.05.

We used linear regression analysis to identify genes in CD45RA^{int}RO^{int} T_{SCM} that correlated with the HIV reservoir decay (Ratio of total HIV DNA (log₁₀)/10⁶ PBMC at day 720 over day 0). We fit a linear model (using R language) between each of the genes and the levels of these outcomes as continuous variables and used GSEA to associate a pathway positively or negatively with both of the readouts (Fig. 2e, 3b, and Supplementary Tables 6 and 7).

Statistical Analysis.

Clinical data (CD4 counts, CD4:CD8 ratio, HIV DNA), CCR5 modification, and flow cytometry analysis:

The paired Wilcoxon rank-sum two-tailed test was used to perform non-parametric donor-paired two-sided analysis to assess the significance of post-infusion changes in total CD4⁺ T cell counts, CD4:CD8 ratio, CD4⁺ T cell subset frequencies and counts, and frequency of total and integrated HIV DNA per 10⁶ cells compared to baseline in the SB-728-0902 study. Missing HIV DNA baseline values for participants 1-01 and 1-02 were estimated by the linear regression model fit intercept. The paired Wilcoxon rank-sum two-tailed test was also used to assess the significance of post-ATI changes in CD4⁺ T cell subset frequencies and counts compared to pre-ATI (week 6) and changes in integrated HIV DNA compared to baseline and pre-ATI (week 6) in the SB-728-1101 study. The Wilcoxon rank-sum two-tailed test was also used to compare the frequency of CCR5 gene-edited alleles, obtained by DNA-Seq, in CD4⁺ T cell memory subsets to that of CD45RA^{int}RO^{int} T_{SCM} in SB-728-T products and post-infusion samples in the SB-728-0902 and SB-728-1101 studies, as well as to compare the levels of transcription factors in CD4⁺ T cell memory subsets to those in CD45RA^{int}RO^{int} T_{SCM} post-infusion, and the frequency of integrated HIV DNA in CD4⁺ T cell memory subsets to that of CD45RA^{int}RO^{int} T_{SCM} in SB-728-T products and post-infusion samples in the SB-728-0902 study. The Wilcoxon rank-sum two-tailed test was also used to compare the diversity of CCR5 gene-edited alleles between SB-738-T products and long-term time points in each CD4⁺ T cell memory subset. The Mann-Whitney two-tailed test was used to perform unpaired non-parametric two-sided comparisons in instances where the number of matched participants varied across time points and contained less than 6 matched pairs at a given time point, such as for the frequencies of CD95⁺ cells post-infusion compared to baseline. A *P* value < 0.05 was considered significant. Statistical analysis was performed using GraphPad Prism v7.0.

The Spearman's rho (ρ) test was used to perform non-parametric correlation analysis to assess the relationship between various measures (e.g., CCR5 gene-edited cells and CD4⁺ T cell subset frequencies and/or counts) and clinical outcomes, including delta CD4⁺ T cell counts post-infusion (SB-728-0902), change in the size of the reservoir calculated using the ratio of year 2 values over baseline post-infusion (SB-728-0902), HIV-specific CD8⁺ T cell effector function post-infusion (SB-728-1101), and control of viral replication post-ATI (SB-728-1101). We controlled for multiple comparison testing by calculating the false discovery rate (FDR) value using the original FDR method of Benjamini and Hochberg⁹³. FDR values are provided in Table 1 and Supplementary Table 3. A *P* value < 0.05 and a *Q* value < 0.25 were considered significant. These statistical analyses were performed using GraphPad Prism v7.0.

Multivariate analysis: A sparse linear multivariate regression model was built to identify features that predict the change in the frequency HIV-infected cells using the "reduction of total HIV DNA in PBMCs between year 2 and baseline" as dependent variable and CD45RA^{int}RO^{int} T_{SCM} cell counts at year 3-4, frequency of Pentamer

Duplication mutations in CD45RA^{int}RO^{int} T_{SCM} post-infusion, ratio of the frequency of Pentamer Duplication in CD45RA^{int}RO^{int} T_{SCM} over the frequency of Pentamer Duplication in T_{EM} at years 3-4, and the number of shared mutations between CD45RA^{int}RO^{int} T_{SCM} and T_{EM} as possible independent variables. Features used, and their values are detailed in Supplementary Table 5. The K-nearest neighbor function implemented in the R package 'impute' (v1.54.0) was used to infer missing values. Default options (k=10) were used. The feature included in the multivariate model were selected by using the LASSO technique as implemented in the R package 'glmnet'. Briefly, the subsets of independent variable minimizing the mean-squared-error was optimized by leave-one-out-cross-validation. The final multivariate model was built on the entire cohort using the features selected using the LASSO technique. Student *t*-test was used to test that the regression coefficient of the independent variables of the final model was statistically different from zero. R-squared value was used to assess the proportion of the dependent variable variance explained by the multivariate model.

1075

1076

1077

1078

1079 **References**

- 1080 1 Kelley, C. F. *et al.* Incomplete peripheral CD4⁺ cell count restoration in HIV-infected
1081 patients receiving long-term antiretroviral treatment. *Clin Infect Dis* **48**, 787-794,
1082 doi:10.1086/597093 (2009).
- 1083 2 Lederman, M. M., Funderburg, N. T., Sekaly, R. P., Klatt, N. R. & Hunt, P. W. Residual
1084 immune dysregulation syndrome in treated HIV infection. *Advances in immunology*
1085 **119**, 51-83, doi:10.1016/B978-0-12-407707-2.00002-3 (2013).
- 1086 3 Lederman, M. M. *et al.* Immunologic failure despite suppressive antiretroviral
1087 therapy is related to activation and turnover of memory CD4 cells. *J Infect Dis* **204**,
1088 1217-1226, doi:10.1093/infdis/jir507 (2011).
- 1089 4 Pinzone, M. R., Di Rosa, M., Cacopardo, B. & Nunnari, G. HIV RNA suppression and
1090 immune restoration: can we do better? *Clin Dev Immunol* **2012**, 515962,
1091 doi:10.1155/2012/515962 (2012).
- 1092 5 Yanik, E. L. *et al.* Incidence and timing of cancer in HIV-infected individuals following
1093 initiation of combination antiretroviral therapy. *Clin Infect Dis* **57**, 756-764,
1094 doi:10.1093/cid/cit369 (2013).
- 1095 6 Serrano-Villar, S. *et al.* HIV-infected individuals with low CD4/CD8 ratio despite
1096 effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8⁺ T cell
1097 activation, and increased risk of non-AIDS morbidity and mortality. *PLoS pathogens*
1098 **10**, e1004078, doi:10.1371/journal.ppat.1004078 (2014).
- 1099 7 Achhra, A. C., Petoumenos, K. & Law, M. G. Relationship between CD4 cell count and
1100 serious long-term complications among HIV-positive individuals. *Curr Opin HIV AIDS*
1101 **9**, 63-71, doi:10.1097/COH.0000000000000017 (2014).
- 1102 8 Freiberg, M. S. *et al.* HIV infection and the risk of acute myocardial infarction. *JAMA*
1103 *Intern Med* **173**, 614-622, doi:10.1001/jamainternmed.2013.3728 (2013).
- 1104 9 Hocqueloux, L. *et al.* Long-term antiretroviral therapy initiated during primary HIV-
1105 1 infection is key to achieving both low HIV reservoirs and normal T cell counts. *J*
1106 *Antimicrob Chemother* **68**, 1169-1178, doi:10.1093/jac/dks533 (2013).
- 1107 10 Pinzone, M. R. *et al.* Monitoring Integration over Time Supports a Role for Cytotoxic
1108 T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size. *J Virol*
1109 **90**, 10436-10445, doi:10.1128/JVI.00242-16 (2016).
- 1110 11 Chun, T. W. *et al.* Presence of an inducible HIV-1 latent reservoir during highly active
1111 antiretroviral therapy. *Proceedings of the National Academy of Sciences of the United*
1112 *States of America* **94**, 13193-13197 (1997).
- 1113 12 Finzi, D. *et al.* Identification of a reservoir for HIV-1 in patients on highly active
1114 antiretroviral therapy. *Science* **278**, 1295-1300 (1997).
- 1115 13 Wong, J. K. *et al.* Recovery of replication-competent HIV despite prolonged
1116 suppression of plasma viremia. *Science* **278**, 1291-1295 (1997).
- 1117 14 Chomont, N. *et al.* HIV reservoir size and persistence are driven by T cell survival
1118 and homeostatic proliferation. *Nat Med* **15**, 893-900, doi:10.1038/nm.1972 (2009).

- 1119 15 Wagner, T. A. *et al.* HIV latency. Proliferation of cells with HIV integrated into cancer
1120 genes contributes to persistent infection. *Science* **345**, 570-573,
1121 doi:10.1126/science.1256304 (2014).
- 1122 16 Maldarelli, F. *et al.* HIV latency. Specific HIV integration sites are linked to clonal
1123 expansion and persistence of infected cells. *Science* **345**, 179-183,
1124 doi:10.1126/science.1254194 (2014).
- 1125 17 Casazza, J. P. *et al.* Therapeutic vaccination expands and improves the function of the
1126 HIV-specific memory T-cell repertoire. *J Infect Dis* **207**, 1829-1840,
1127 doi:10.1093/infdis/jit098 (2013).
- 1128 18 Shive, C. L. *et al.* Inflammation Perturbs the IL-7 Axis, Promoting Senescence and
1129 Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection. *J*
1130 *Acquir Immune Defic Syndr* **71**, 483-492, doi:10.1097/QAI.0000000000000913
1131 (2016).
- 1132 19 Nakanjako, D. *et al.* High T-cell immune activation and immune exhaustion among
1133 individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in
1134 an African cohort. *BMC Infect Dis* **11**, 43, doi:10.1186/1471-2334-11-43 (2011).
- 1135 20 Boulassel, M. R. *et al.* CD4 T cell nadir independently predicts the magnitude of the
1136 HIV reservoir after prolonged suppressive antiretroviral therapy. *J Clin Virol* **53**, 29-
1137 32, doi:10.1016/j.jcv.2011.09.018 (2012).
- 1138 21 Hutter, G. *et al.* Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell
1139 transplantation. *N Engl J Med* **360**, 692-698, doi:10.1056/NEJMoa0802905 (2009).
- 1140 22 Allers, K. *et al.* Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem
1141 cell transplantation. *Blood* **117**, 2791-2799, doi:10.1182/blood-2010-09-309591
1142 (2011).
- 1143 23 Walter, E. A. *et al.* Reconstitution of cellular immunity against cytomegalovirus in
1144 recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. *N*
1145 *Engl J Med* **333**, 1038-1044, doi:10.1056/NEJM199510193331603 (1995).
- 1146 24 Heslop, H. E. *et al.* Long-term restoration of immunity against Epstein-Barr virus
1147 infection by adoptive transfer of gene-modified virus-specific T lymphocytes. *Nature*
1148 *medicine* **2**, 551-555 (1996).
- 1149 25 Koenig, S. *et al.* Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS
1150 patient leads to selection for mutant HIV variants and subsequent disease
1151 progression. *Nature medicine* **1**, 330-336 (1995).
- 1152 26 Levine, B. L. *et al.* Adoptive transfer of costimulated CD4+ T cells induces expansion
1153 of peripheral T cells and decreased CCR5 expression in HIV infection. *Nature*
1154 *medicine* **8**, 47-53, doi:10.1038/nm0102-47 (2002).
- 1155 27 Mitsuyasu, R. T. *et al.* Prolonged survival and tissue trafficking following adoptive
1156 transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human
1157 immunodeficiency virus-infected subjects. *Blood* **96**, 785-793 (2000).
- 1158 28 Deeks, S. G. *et al.* A phase II randomized study of HIV-specific T-cell gene therapy in
1159 subjects with undetectable plasma viremia on combination antiretroviral therapy.
1160 *Mol Ther* **5**, 788-797, doi:10.1006/mthe.2002.0611 (2002).
- 1161 29 Perez, E. E. *et al.* Establishment of HIV-1 resistance in CD4+ T cells by genome
1162 editing using zinc-finger nucleases. *Nature biotechnology* **26**, 808-816,
1163 doi:10.1038/nbt1410 (2008).
- 1164 30 Tebas, P. *et al.* Gene editing of CCR5 in autologous CD4 T cells of persons infected
1165 with HIV. *N Engl J Med* **370**, 901-910, doi:10.1056/NEJMoa1300662 (2014).
- 1166 31 Gattinoni, L. *et al.* A human memory T cell subset with stem cell-like properties. *Nat*
1167 *Med* **17**, 1290-1297, doi:10.1038/nm.2446 (2011).

1168 32 Lugli, E. *et al.* Identification, isolation and in vitro expansion of human and
1169 nonhuman primate T stem cell memory cells. *Nat Protoc* **8**, 33-42,
1170 doi:10.1038/nprot.2012.143 (2013).
1171 33 Robert, L. *et al.* CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
1172 *Clin Cancer Res* **20**, 2424-2432, doi:10.1158/1078-0432.CCR-13-2648 (2014).
1173 34 Becht, E. *et al.* Dimensionality reduction for visualizing single-cell data using UMAP.
1174 *Nat Biotechnol*, doi:10.1038/nbt.4314 (2018).
1175 35 Cieri, N. *et al.* IL-7 and IL-15 instruct the generation of human memory stem T cells
1176 from naive precursors. *Blood* **121**, 573-584, doi:10.1182/blood-2012-05-431718
1177 (2013).
1178 36 Gattinoni, L. *et al.* Wnt signaling arrests effector T cell differentiation and generates
1179 CD8+ memory stem cells. *Nat Med* **15**, 808-813, doi:10.1038/nm.1982 (2009).
1180 37 Yang, C. Y. *et al.* The transcriptional regulators Id2 and Id3 control the formation of
1181 distinct memory CD8+ T cell subsets. *Nat Immunol* **12**, 1221-1229,
1182 doi:10.1038/ni.2158 (2011).
1183 38 Ji, Y. *et al.* Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the
1184 formation of memory CD8+ T cells. *Nat Immunol* **12**, 1230-1237,
1185 doi:10.1038/ni.2153 (2011).
1186 39 Okoye, A. *et al.* Progressive CD4+ central memory T cell decline results in CD4+
1187 effector memory insufficiency and overt disease in chronic SIV infection. *J Exp Med*
1188 **204**, 2171-2185, doi:10.1084/jem.20070567 (2007).
1189 40 Canoui, E. *et al.* A Subset of Extreme Human Immunodeficiency Virus (HIV)
1190 Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell
1191 Activation Level. *Open Forum Infect Dis* **4**, ofx064, doi:10.1093/ofid/ofx064 (2017).
1192 41 Miura, T. *et al.* HLA-B57/B*5801 human immunodeficiency virus type 1 elite
1193 controllers select for rare gag variants associated with reduced viral replication
1194 capacity and strong cytotoxic T-lymphocyte [corrected] recognition. *J Virol* **83**,
1195 2743-2755, doi:10.1128/JVI.02265-08 (2009).
1196 42 Jansen, C. A. *et al.* High responsiveness of HLA-B57-restricted Gag-specific CD8+ T
1197 cells in vitro may contribute to the protective effect of HLA-B57 in HIV-infection. *Eur*
1198 *J Immunol* **35**, 150-158, doi:10.1002/eji.200425487 (2005).
1199 43 van Lunzen, J. *et al.* Transfer of autologous gene-modified T cells in HIV-infected
1200 patients with advanced immunodeficiency and drug-resistant virus. *Molecular*
1201 *therapy : the journal of the American Society of Gene Therapy* **15**, 1024-1033,
1202 doi:10.1038/mt.sj.6300124 (2007).
1203 44 Tebas, P. *et al.* Antiviral effects of autologous CD4 T cells genetically modified with a
1204 conditionally replicating lentiviral vector expressing long antisense to HIV. *Blood*
1205 **121**, 1524-1533, doi:10.1182/blood-2012-07-447250 (2013).
1206 45 Riddell, S. R. *et al.* T-cell mediated rejection of gene-modified HIV-specific cytotoxic
1207 T lymphocytes in HIV-infected patients. *Nat Med* **2**, 216-223, doi:10.1038/nm0296-
1208 216 (1996).
1209 46 Zhen, A. *et al.* HIV-specific Immunity Derived From Chimeric Antigen Receptor-
1210 engineered Stem Cells. *Mol Ther* **23**, 1358-1367, doi:10.1038/mt.2015.102 (2015).
1211 47 Besson, G. J. *et al.* HIV-1 DNA decay dynamics in blood during more than a decade of
1212 suppressive antiretroviral therapy. *Clin Infect Dis* **59**, 1312-1321,
1213 doi:10.1093/cid/ciu585 (2014).
1214 48 Tsai, P. *et al.* In vivo analysis of the effect of panobinostat on cell-associated HIV RNA
1215 and DNA levels and latent HIV infection. *Retrovirology* **13**, 36, doi:10.1186/s12977-
1216 016-0268-7 (2016).

1217 49 Archin, N. M. *et al.* HIV-1 expression within resting CD4⁺ T cells after multiple doses
1218 of vorinostat. *J Infect Dis* **210**, 728-735, doi:10.1093/infdis/jiu155 (2014).
1219 50 Archin, N. M. *et al.* Administration of vorinostat disrupts HIV-1 latency in patients on
1220 antiretroviral therapy. *Nature* **487**, 482-485, doi:10.1038/nature11286 (2012).
1221 51 Elliott, J. H. *et al.* Activation of HIV transcription with short-course vorinostat in HIV-
1222 infected patients on suppressive antiretroviral therapy. *PLoS pathogens* **10**,
1223 e1004473, doi:10.1371/journal.ppat.1004473 (2014).
1224 52 Leth, S. *et al.* Combined effect of Vacc-4x, recombinant human granulocyte
1225 macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1
1226 reservoir (REDUC): a single-arm, phase 1B/2A trial. *Lancet HIV* **3**, e463-472,
1227 doi:10.1016/S2352-3018(16)30055-8 (2016).
1228 53 Alvarez-Fernandez, C., Escriba-Garcia, L., Vidal, S., Sierra, J. & Briones, J. A short
1229 CD3/CD28 costimulation combined with IL-21 enhance the generation of human
1230 memory stem T cells for adoptive immunotherapy. *J Transl Med* **14**, 214,
1231 doi:10.1186/s12967-016-0973-y (2016).
1232 54 Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health
1233 and disease. *Nat Med* **23**, 18-27, doi:10.1038/nm.4241 (2017).
1234 55 Biasco, L. *et al.* In vivo tracking of T cells in humans unveils decade-long survival and
1235 activity of genetically modified T memory stem cells. *Sci Transl Med* **7**, 273ra213,
1236 doi:10.1126/scitranslmed.3010314 (2015).
1237 56 Etzrodt, M., Ende, M. & Schroeder, T. Quantitative single-cell approaches to stem
1238 cell research. *Cell Stem Cell* **15**, 546-558, doi:10.1016/j.stem.2014.10.015 (2014).
1239 57 Kuo, C. Y. *et al.* Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-
1240 Linked Hyper-IgM Syndrome. *Cell Rep* **23**, 2606-2616,
1241 doi:10.1016/j.celrep.2018.04.103 (2018).
1242 58 Long, J. *et al.* Characterization of Gene Alterations following Editing of the beta-
1243 Globin Gene Locus in Hematopoietic Stem/Progenitor Cells. *Molecular therapy: the*
1244 *journal of the American Society of Gene Therapy* **26**, 468-479,
1245 doi:10.1016/j.ymthe.2017.11.001 (2018).
1246 59 Nie, C. *et al.* Selective infection of CD4⁺ effector memory T lymphocytes leads to
1247 preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized
1248 NOD/SCID/IL-2R γ manull mice. *Virology* **394**, 64-72,
1249 doi:10.1016/j.virol.2009.08.011 (2009).
1250 60 Flynn, J. K. *et al.* Quantifying susceptibility of CD4⁺ stem memory T-cells to infection
1251 by laboratory adapted and clinical HIV-1 strains. *Viruses* **6**, 709-726,
1252 doi:10.3390/v6020709 (2014).
1253 61 Buzon, M. J. *et al.* HIV-1 persistence in CD4⁺ T cells with stem cell-like properties.
1254 *Nat Med* **20**, 139-142, doi:10.1038/nm.3445 (2014).
1255 62 Jaafoura, S. *et al.* Progressive contraction of the latent HIV reservoir around a core of
1256 less-differentiated CD4(+) memory T Cells. *Nat Commun* **5**, 5407,
1257 doi:10.1038/ncomms6407 (2014).
1258 63 Palmer, S. *et al.* Low-level viremia persists for at least 7 years in patients on
1259 suppressive antiretroviral therapy. *Proceedings of the National Academy of Sciences*
1260 *of the United States of America* **105**, 3879-3884, doi:10.1073/pnas.080050105
1261 (2008).
1262 64 Sahu, G. K., Sarria, J. C. & Cloyd, M. W. Recovery of replication-competent residual
1263 HIV-1 from plasma of a patient receiving prolonged, suppressive highly active
1264 antiretroviral therapy. *J Virol* **84**, 8348-8352, doi:10.1128/JVI.00362-10 (2010).

1265 65 Buzon, M. J. *et al.* HIV-1 replication and immune dynamics are affected by raltegravir
1266 intensification of HAART-suppressed subjects. *Nature medicine* **16**, 460-465,
1267 doi:10.1038/nm.2111 (2010).
1268 66 van Zyl, G., Bale, M. J. & Kearney, M. F. HIV evolution and diversity in ART-treated
1269 patients. *Retrovirology* **15**, 14, doi:10.1186/s12977-018-0395-4 (2018).
1270 67 Cartwright, E. K. *et al.* CD8(+) Lymphocytes Are Required for Maintaining Viral
1271 Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral
1272 Therapy. *Immunity* **45**, 656-668, doi:10.1016/j.immuni.2016.08.018 (2016).
1273 68 Simonetti, F. R. *et al.* Clonally expanded CD4+ T cells can produce infectious HIV-1 in
1274 vivo. *Proceedings of the National Academy of Sciences of the United States of America*
1275 **113**, 1883-1888, doi:10.1073/pnas.1522675113 (2016).
1276 69 Fletcher, C. V. *et al.* Persistent HIV-1 replication is associated with lower
1277 antiretroviral drug concentrations in lymphatic tissues. *Proceedings of the National*
1278 *Academy of Sciences of the United States of America* **111**, 2307-2312,
1279 doi:10.1073/pnas.1318249111 (2014).
1280 70 Lorenzo-Redondo, R. *et al.* Persistent HIV-1 replication maintains the tissue
1281 reservoir during therapy. *Nature* **530**, 51-56, doi:10.1038/nature16933 (2016).
1282 71 Paiardini, M. *et al.* Low levels of SIV infection in sooty mangabey central memory
1283 CD(4)(+) T cells are associated with limited CCR5 expression. *Nature medicine* **17**,
1284 830-836, doi:10.1038/nm.2395 (2011).
1285 72 Klatt, N. R. *et al.* Limited HIV infection of central memory and stem cell memory
1286 CD4+ T cells is associated with lack of progression in viremic individuals. *PLoS*
1287 *pathogens* **10**, e1004345, doi:10.1371/journal.ppat.1004345 (2014).
1288 73 Noel, N. *et al.* Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency
1289 of Infected Cells and Inefficient Viral Reactivation. *J Virol* **90**, 6148-6158,
1290 doi:10.1128/JVI.00419-16 (2016).
1291 74 O'Connell, K. A. *et al.* Control of HIV-1 in elite suppressors despite ongoing
1292 replication and evolution in plasma virus. *J Virol* **84**, 7018-7028,
1293 doi:10.1128/JVI.00548-10 (2010).
1294 75 O'Connell, K. A., Hegarty, R. W., Siliciano, R. F. & Blankson, J. N. Viral suppression of
1295 multiple escape mutants by de novo CD8(+) T cell responses in a human
1296 immunodeficiency virus-1 infected elite suppressor. *Retrovirology* **8**, 63,
1297 doi:10.1186/1742-4690-8-63 (2011).
1298 76 Bailey, J. R., Brennan, T. P., O'Connell, K. A., Siliciano, R. F. & Blankson, J. N. Evidence
1299 of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type
1300 1 nef in HLA-B*57+ elite suppressors. *J Virol* **83**, 88-97, doi:10.1128/JVI.01958-08
1301 (2009).
1302 77 Conway, J. M. & Perelson, A. S. Post-treatment control of HIV infection. *Proc Natl*
1303 *Acad Sci U S A* **112**, 5467-5472, doi:10.1073/pnas.1419162112 (2015).
1304 78 Shan, L. *et al.* Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates
1305 elimination of latent viral reservoir after virus reactivation. *Immunity* **36**, 491-501,
1306 doi:10.1016/j.immuni.2012.01.014 (2012).
1307 79 Matloubian, M., Concepcion, R. J. & Ahmed, R. CD4+ T cells are required to sustain
1308 CD8+ cytotoxic T-cell responses during chronic viral infection. *J Virol* **68**, 8056-8063
1309 (1994).
1310 80 Aubert, R. D. *et al.* Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells
1311 during chronic viral infection. *Proceedings of the National Academy of Sciences of the*
1312 *United States of America* **108**, 21182-21187, doi:10.1073/pnas.1118450109 (2011).

- 1313 81 Gannon, P. O. *et al.* Rapid and Continued T-Cell Differentiation into Long-term
1314 Effector and Memory Stem Cells in Vaccinated Melanoma Patients. *Clin Cancer Res*
1315 **23**, 3285-3296, doi:10.1158/1078-0432.CCR-16-1708 (2017).
- 1316 82 Maier, D. A. *et al.* Efficient clinical scale gene modification via zinc finger nuclease-
1317 targeted disruption of the HIV co-receptor CCR5. *Human gene therapy* **24**, 245-258,
1318 doi:10.1089/hum.2012.172 (2013).
- 1319 83 Anton, P. A. *et al.* Enhanced levels of functional HIV-1 co-receptors on human
1320 mucosal T cells demonstrated using intestinal biopsy tissue. *AIDS* **14**, 1761-1765
1321 (2000).
- 1322 84 Ganusov, V. V. & De Boer, R. J. Do most lymphocytes in humans really reside in the
1323 gut? *Trends in immunology* **28**, 514-518, doi:10.1016/j.it.2007.08.009 (2007).
- 1324 85 Needleman, S. B. & Wunsch, C. D. A general method applicable to the search for
1325 similarities in the amino acid sequence of two proteins. *Journal of molecular biology*
1326 **48**, 443-453 (1970).
- 1327 86 Anton, P. A. *et al.* Sensitive and reproducible quantitation of mucosal HIV-1 RNA and
1328 DNA viral burden in patients with detectable and undetectable plasma viral HIV-1
1329 RNA using endoscopic biopsies. *Journal of virological methods* **95**, 65-79 (2001).
- 1330 87 Vandergeeten, C. *et al.* Cross-clade ultrasensitive PCR-based assays to measure HIV
1331 persistence in large-cohort studies. *J Virol* **88**, 12385-12396,
1332 doi:10.1128/JVI.00609-14 (2014).
- 1333 88 Shannon, C. E. The mathematical theory of communication. 1963. *M.D. computing :*
1334 *computers in medical practice* **14**, 306-317 (1997).
- 1335 89 The R Development Core Team. *R: A Language and Environment for Statistical*
1336 *Computing*. (R Foundation for Statistical Computing, 2010).
- 1337 90 Smyth, G. K. in *Bioinformatics and Computational Biology Solutions using R and*
1338 *Bioconductor* (Springer, 2005).
- 1339 91 Gentleman, R. C. *et al.* Bioconductor: open software development for computational
1340 biology and bioinformatics. *Genome Biol* **5**, R80, doi:10.1186/gb-2004-5-10-r80
1341 (2004).
- 1342 92 Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of
1343 normalization methods for high density oligonucleotide array data based on
1344 variance and bias. *Bioinformatics* **19**, 185-193 (2003).
- 1345 93 Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
1346 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series*
1347 *B (Methodological)* **57**, 289-300 (1995).
- 1348 94 Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach
1349 for interpreting genome-wide expression profiles. *Proceedings of the National*
1350 *Academy of Sciences of the United States of America* **102**, 15545-15550,
1351 doi:10.1073/pnas.0506580102 (2005).

1352

1353

Table 1. Correlation of increase in circulating CD4⁺ T cell subsets (delta cell count compared to BL) at early (day 14), mid (month 4-7), late (month 11-12) and long-term time points (years 3-4) with immune reconstitution (delta CD4⁺ count compared to BL) at the same time points.

		Spearman rank correlation ρ	<i>P</i> value	q value (FDR)	<i>n</i>
Delta CD4 ⁺ count (cell/ μ L) days 14-28	Delta CD45RA ⁺ CD45RO ⁻ CCR7 ⁺ CD27 ⁺ (cell/ μ L) d14-28	0.7714	0.1028	0.1645	6
	Delta Total CD45RA ^{int} RO ^{int} (cell/ μ L) d14-28	0.7714	0.2972	0.3963	6
	Delta T _{CM} (cell/ μ L) d14-28	0.9429	0.0167*	0.0668*	6
	Delta T _{TM} (cell/ μ L) d14-28	1	0.0028*	0.0224*	6
	Delta T _{EM} (cell/ μ L) d14-28	0.8286	0.0583	0.1104	6
Delta CD4 ⁺ count (cell/ μ L) months 4-7	Delta CD45RA ⁺ CD45RO ⁻ CCR7 ⁺ CD27 ⁺ (cell/ μ L) m4-7	0.7857	0.0279*	0.0744*	8
	Delta Total CD45RA ^{int} RO ^{int} (cell/ μ L) m4-7	0.6905	0.0694	0.1190	8
	Delta T _{CM} (cell/ μ L) m4-7	0.8333	0.0154*	0.0668*	8
	Delta T _{TM} (cell/ μ L) m4-7	0.7619	0.0368*	0.0803*	8
	Delta T _{EM} (cell/ μ L) m4-7	0.1667	0.7033	0.7788	8
Delta CD4 ⁺ count (cell/ μ L) months 11-12	Delta CD45RA ⁺ CD45RO ⁻ CCR7 ⁺ CD27 ⁺ (cell/ μ L) m11-12	0.75	0.0255*	0.0744*	9
	Delta Total CD45RA ^{int} RO ^{int} (cell/ μ L) m11-12	0.8667	0.0045*	0.0270*	9
	Delta T _{CM} (cell/ μ L) m11-12	0.9	0.0020*	0.0224*	9
	Delta T _{TM} (cell/ μ L) m11-12	0.75	0.0255*	0.0744*	9
	Delta T _{EM} (cell/ μ L) m11-12	0.2833	0.4630	0.5556	9
Delta CD4 ⁺ count (cell/ μ L) years 3-4	Delta CD45RA ⁺ CD45RO ⁻ CCR7 ⁺ CD27 ⁺ (cell/ μ L) yr3-4	0.6611	0.0598	0.1104	9
	Delta Total CD45RA ^{int} RO ^{int} (cell/ μ L) yr3-4	0.887	0.0025*	0.0224*	9
	Delta T _{CM} (cell/ μ L) yr3-4	0.477	0.1974	0.2787	9
	Delta T _{TM} (cell/ μ L) yr3-4	0.3347	0.3738	0.4722	9
	Delta T _{EM} (cell/ μ L) yr3-4	-0.03347	0.9374	0.9374	9
	Delta naive (cell/ μ L) yr3-4	-0.2000	0.7139	0.7788	6
	Delta CD45RA ⁺ T _{SCM} (cell/ μ L) yr3-4	0.7143	0.1361	0.2042	6
	Delta CD45RA ^{int} RO ^{int} T _{SCM} (cell/ μ L) yr3-4	0.8857	0.0333*	0.0799*	6
	Delta CD45RA ^{int} RO ^{int} CD95 ⁻ (cell/ μ L) yr3-4	0.1429	0.8028	0.8377	6

* Significant correlations with *P* < 0.05 and false discovery rate (FDR) < 0.25

CD45RA⁺CD45RO⁻CCR7⁺CD27⁺ cells include naïve (CD95⁻) and CD45RA⁺T_{SCM}(CD95⁺) cells

CD45RA^{int}RO^{int} cells are defined as CD45RA^{int} and CD45RO^{int}

T_{CM} cells are defined as CD45RA⁻, CD45RO⁺, CCR7⁺, and CD27⁺

T_{TM} cells are defined as CD45RA⁻, CD45RO⁺, CCR7⁻, and CD27⁺

T_{EM} cells are defined as CD45RA⁻, CD45RO⁺, CCR7⁻, and CD27⁻

CD45RA^{int}RO^{int} T_{SCM} are defined as CD45RA^{int}, CD45RO^{int}, CCR7⁺, CD27⁺, CD127⁺, CD28⁺, CD58⁺, and CD95⁺

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5